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Abstract
This dissertation expands upon 8 published studies (Ananth, Engelsmann, & Kiriakos, 1980; Burdick &
Holmes, 1980; Campbell & Kimball, 1984; Donnelly, Goodwin, Waldman, & Murphy, 1978; Garvy, Johnson,
Valentine, & Schuster, 1983; House & Martin, 1975; Steinberg, 1979; Steinbook & Chapman, 1970) that
have examined the ability of the Minnesota Multiphasic Personality Inventory (MMPI) to discern lithium
response. Using records from an adolescent inpatient facility, Minnesota Multiphasic Personality Inventory-
Adolescent (MMPI-A) responses of lithium responders and non-responders were assessed for group
differences. Participants were 29 adolescents (14 males, 18 females) between the ages of 14 and 18 years (M =
16.0, SD = 1.2). Lithium response was assessed using Global Assessment of Functioning (GAF) scores and
change in number of critical incidents. Independent samples t-tests indicated no significant differences (p <
.05) between groups on the MMPI-A validity and clinical scales, or on reconstructed versions of Schaffer’s
(1963) Acquiescence (Ac) scale or the Lithium Response-Female (LRS-FM) and Lithium Response-Male
(LRS-M) scales (Donnelly et al.). Effect sizes for Scale 2 (d = -0.79) and LRS-F (d = -0.77) suggest responders
may have noticeably lower scores on these scales than non-responders. Multiple linear regressions were
modeled to control for group differences between participants who completed the MMPI-A within 14 days of
beginning lithium administration and those who completed it after 14 days or more of lithium administration.
These models indicated no significant results. Limitations are discussed and future research is recommended,
based on effect size findings.
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ABSTRACT 
This dissertation expands upon 8 published studies (Ananth, Engelsmann, & 
Kiriakos, 1980; Burdick & Holmes, 1980; Campbell & Kimball, 1984; Donnelly, 
Goodwin, Waldman, & Murphy, 1978; Garvy, Johnson, Valentine, & Schuster, 1983; 
House & Martin, 1975; Steinberg, 1979; Steinbook & Chapman, 1970) that have 
examined the ability of the Minnesota Multiphasic Personality Inventory (MMPI) to 
discern lithium response. Using records from an adolescent inpatient facility, Minnesota 
Multiphasic Personality Inventory- Adolescent (MMPI-A) responses of lithium 
responders and non-responders were assessed for group differences. Participants were 29 
adolescents (14 males, 18 females) between the ages of 14 and 18 years (M = 16.0, SD = 
1.2). Lithium response was assessed using Global Assessment of Functioning (GAF) 
scores and change in number of critical incidents. Independent samples t-tests indicated 
no significant differences (p < .05) between groups on the MMPI-A validity and clinical 
scales, or on reconstructed versions of Schaffer’s (1963) Acquiescence (Ac) scale or the 
Lithium Response-Female (LRS-F) and Lithium Response-Male (LRS-M) scales 
(Donnelly et al.). Effect sizes for Scale 2 (d = -0.79) and LRS-F (d = -0.77) suggest 
responders may have noticeably lower scores on these scales than non-responders. 
Multiple linear regressions were modeled to control for group differences between 
participants who completed the MMPI-A within 14 days of beginning lithium 
administration and those who completed it after 14 days or more of lithium 
administration. These models indicated no significant results. Limitations are discussed 
and future research is recommended, based on effect size findings.     
Key Terms: assessment, MMPI-A, lithium response, clinical scales, effect size  
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REVIEW OF THE LITERATURE ON THE MMPI AND LITHIUM RESPONSE 
Lithium is a commonly prescribed drug in both adult and child/adolescent 
populations (Bhangoo et al., 2003; Grof, 2003; Hunkeler et al., 2005; Najjar et al., 2004; 
Smith, Cornelius, Warnock, Tacchi, & Taylor, 2007; Weller, Calvert, & Weller, 2003). 
However, despite its widespread use in these populations, there are a significant number 
of individuals for whom lithium is not effective (Julien, 2005). In order to maximize 
treatment effectiveness and efficiency, it would be useful to have a simple, valid and 
reliable method of predicting lithium response (Campbell & Kimball, 1984). Following 
this rationale, a branch of research emerged between 1970 and 1984 that examined the 
relationship in adults between responses on a reliable and well validated psychological 
instrument, the Minnesota Multiphasic Personality Inventory (MMPI), and clinical 
response to lithium. Unfortunately, this branch of research extinguished before solid 
conclusions could be reached regarding the utility of MMPI response patterns in 
determining lithium response. The purpose of this study is to revisit and expand upon the 
previous research by investigating the utility of the Minnesota Multiphasic Personality 
Inventory- Adolescent (MMPI-A) as an instrument for evaluating lithium response in a 
local population of adolescent inpatients.  
Lithium 
Although there was published evidence of lithium’s mood stabilizing effects as 
early as 1949 (Cade, 1949), the drug was not widely accepted as a treatment for bipolar 
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disorder until the 1970s (Julien, 2005). Since the establishment of lithium’s superiority to 
placebo, the drug has “historically been the most recommended drug for treating bipolar 
disorder and reducing its rate of relapse” (Julien, p. 310). Further, the American 
Psychiatric Association’s treatment guidelines for bipolar disorder recommend Lithium 
in conjunction with an atypical antipsychotic as one of the two treatments of choice for 
severe manic or mixed episodes and lithium monotherapy as one of the three primary 
drugs for treating less severe episodes (American Psychiatric Association, 2002). As a 
monotherapy, lithium is an effective prophylactic treatment for approximately 60 to 70% 
of people who have bipolar disorder. It is also an effective treatment for acute mania and 
mixed episodes and, to a lesser extent, depressive episodes (Julien, 2005). However, 
approximately 40% of people who have bipolar disorders either have symptoms that are 
refractory to lithium or suffer efficacy interfering side effects. Therefore, lithium is also 
frequently used in combination with other medications, particularly antiepileptic drugs, to 
increase efficacy. In fact, combination therapy is more common than lithium 
monotherapy in many instances (Julien, p. 316). 
 Although lithium is still a first line pharmacological treatment for bipolar 
disorder, the drug does have significant risks associated with its consumption that should 
be noted. Common mild to moderate side effects of lithium include: gastrointestinal 
problems (such as nausea, vomiting, diarrhea, and abdominal pain); neurological 
difficulties (such as tremor, lethargy, impaired concentration, dizziness, slurred speech, 
ataxia, muscle weakness, and nystagmus); memory problems; weight gain; polyuria; and 
polydypsia (Dwyer Schull, 2005; Julien, 2005). Further, in lithium blood plasma levels 
above 2.0 mEq/L, a potentially fatal state of “lithium toxicity” can occur (Julien, p. 313). 
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Toxicity can involve more severe forms of previously mentioned side effects, such as 
more severe tremors, muscle weakness, and slurred speech. It can also lead to depressed 
thyroid functioning, muscle fasciculations, abnormal motor movements, increased 
reflexes, psychosis, and stupor. In its most severe forms, toxicity can result in muscle 
rigidity, coma, renal failure, cardiac arrhythmias, and death. 
 A steady state of lithium in blood plasma is typically reached after 2 weeks of 
drug administration (Julien, 2005, p. 313). During the 1980s through the early 1990s, 
adult therapeutic plasma levels of lithium were considered to be between 0.75 and 1.0 
milliequivalents per liter (mEq/L) of blood. More recent recommendations are for levels 
between 0.5 and 0.7 mEq/L, with some guidelines allowing up to a maximum level of 1.2 
mEq/L (Julien, p. 312). This range between the minimum effective dosage and the 
maximum dosage that is considered safe is known as the therapeutic index. In the case of 
lithium, the therapeutic index is considered to be very narrow and necessitates frequent 
monitoring of patients’ blood serum levels (Julien, p. 312).  
Despite its recognized difficulties with side effects, potential for toxicity, and 
long-term adherence, lithium is still considered by many to be the pharmacological “gold 
standard” for treating bipolar disorder (Julien, 2005, p. 311). Due to the risks associated 
with lithium treatment and the range of responsiveness to the drug, the ability to 
differentiate between patients likely to respond to treatment and those not likely to 
respond has long been of interest to researchers and practitioners. Various approaches to 
ascertaining lithium responsiveness have been explored and include: immediate familial 
history of bipolar disorder and/ or lithium responsiveness (see, for example, Strober et al., 
1988), neuro-physiological features of those responsive to lithium (see, for example, 
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Davanzo et al., 2001), and symptom patterns and/or clinical features of those responsive 
to lithium (see, for example, Bowden et al., 2005). One sub-group of research within the 
category of investigating clinical features includes research on the association between 
MMPI response characteristics and lithium response. 
The MMPI 
The Minnesota Multiphasic Personality Inventory (MMPI) is the most widely 
used and extensively researched objective personality inventory (Greene, 2000; Archer & 
Krishnamurthy, 2002). First created in 1940 (Hathaway & McKinley), it was 
subsequently updated, restandardized, and published as the MMPI-2 in 1989 (Butcher, 
Dahlstrom, Graham, Tellegen, & Kaemmer). In 1992, the Minnesota Multiphasic 
Personality Inventory- Adolescent (MMPI-A) was published (Butcher et al., 1992). This 
most recent addition to the MMPI instruments utilized adolescent normative samples and 
adapted content to increase relevance and accessibility to adolescent test-takers. Although 
the original MMPI was frequently used with adolescents, (Archer, Maruish, Imhof, & 
Piotrowski, 1991), the length, language, available norms, and lack of adolescent-specific 
item content raised concerns about the use of the MMPI with adolescent populations 
(Archer & Krishnamurthy).  
When creating the MMPI-2 and the MMPI-A, significant care was taken to 
maximize continuity across prior versions of the instrument. For example, during 
construction of the MMPI-A, item pools for 8 of the 10 basic clinical scales “were 
essentially held intact with only minor revisions to some items to improve clarity” 
(Archer & Krishnamurthy, 2002, p. 12). However, one validity scale and two clinical 
scales were extensively revised. The F scale was changed to more accurately reflect items 
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infrequently endorsed by adolescents and Scales 5 and 0 where shortened (Archer & 
Krishnamurthy). Overall, “the clinical correlates found for the basic clinical scales of the 
MMPI, MMPI-2, and MMPI-A show a high degree of consistency” (Archer & 
Krishnamurthy, p. 18). Other similarities and differences between the MMPI, MMPI-2, 
and MMPI-A are beyond the scope of this investigation; however, general consensus 
holds that reliability and validity of all three instruments have been firmly established. 
The respective manuals for the MMPI-2 and the MMPI-A thoroughly address various 
forms of reliability and validity, as well as test construction and continuity issues between 
test versions. The reader may also wish to consult secondary sources such as Greene 
(2000), Archer & Krishnamurthy (2002), or Nichols (2001) for further discussion of test 
construction, validation, and continuity with previous editions.  
The MMPI and MMPI-2 are among the most frequently used psychological tests 
across professional settings (Greene, 2000). One investigation indicated the MMPI was 
utilized by 91% of surveyed psychologists in psychiatric hospitals (Lubin, Larsen, 
Matarazzo, & Seever, 1985). Another report indicated that 93% of surveyed 
psychologists utilized the MMPI-2 at least occasionally (Watkins, Campbell, Nieberding, 
& Hallmark, 1995). The same study also reported the measure ranked among the top 10 
most utilized instruments across the seven professional settings that were surveyed: 
private practice, mental hospital, general hospital, community mental health 
center/outpatient clinic, university department, medical school, or other. 
The MMPI’s frequent use across various clinical settings can partly be attributed 
to the wide research base that exists on the instrument’s reliability, validity, and utility 
across specific population groups. Indeed, research has been conducted using the 
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different versions of the MMPI to discern population characteristics in groups as diverse 
as people with substance abuse issues and those with brain injuries (Archer & 
Krishnamurthy, 2002).  It is no surprise then, that the MMPI was utilized for research 
into the relationship between test response characteristics and response to lithium. For 
example, House and Martin (1975) argued the following advantages of using the MMPI 
in the “isolation of pretreatment variables helpful in predicting pharmacologic response” 
(p. 646). The MMPI is readily available, administration is low risk, and it can be 
expediently scored and interpreted. By contrast, they asserted medication trials, the more 
common method of assessing medication response within a diagnostic category, are 
“costly, time consuming, and have the potential for adverse effects” (p. 646).  
 Previous Research 
The previous research on the association between Lithium response and MMPI 
response patterns that is reviewed in the current investigation was identified via a search 
of four electronic databases (PsycInfo, Medline, ERIC, and Academic Search Premier). 
The search terms used were “lithium”, “Minnesota Multiphasic Personality Inventory 
(MMPI)”, and “Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-A)”. 
The inclusion criteria for this search were: the article was published in English in a peer-
reviewed professional psychology or psychiatric journal, and the focus of the study was 
on the relationship between lithium response and MMPI responses. Articles that 
examined the relationship between the MMPI and response to other psychotropic 
medications were excluded, as were articles that focused on other means of predicting 
lithium response such as family history, biological features, etc. Please note, multiple 
versions of the MMPI (MMPI, MMPI-2, and MMPI-A) were included in this search. An 
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investigation of the reference lists for gathered articles was also conducted to include any 
relevant articles that the initial search did not recover. To the author’s knowledge, the 
current study is the first investigation into the association between adolescent lithium 
response and the MMPI-A.  
The aforementioned search strategy yielded a total of eight published studies that 
examined the relationship between MMPI responses and lithium response. Review of 
these studies indicated the authors of four studies reported they found statistically 
significant results (Steinbook & Chapman, 1970; House & Martin, 1975; Donnelly, 
Goodwin, Waldman, & Murphy, 1978; Steinberg, 1979), while the authors of one study 
asserted they had found notable trends amongst results, although no statistical 
significance was found (Ananth, Engelsmann, & Kiriakos, 1980). The authors of the 
three remaining studies found no significant results (Burdick & Holmes, 1980; Garvey, 
Johnson, Valentine, & Schuster, 1983; and Campbell & Kimball, 1984). All three of the 
studies that did not find statistically significant results were replications of Donnelly et al. 
It is important to note that the definition of lithium response varied across the completed 
studies. Some studies examined antidepressant, or prophylactic effects of the drug, while 
others examined a combination of the drug’s effects on various agitated states across 
disorders, including antimanic effects. Still others did not specify what affective state was 
being targeted. For example, Steinbook and Chapman (1970), who authored the first 
published study, did not specify the affective state targeted by lithium during their drug 
trial, although they appeared to be targeting patients who were experiencing various 
forms of pathological agitation or excitation. By contrast, House and Martin (1975) 
specifically targeted antidepressant effects of the drug. The variability in target states 
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used in the various studies could likely affect the construct validity of lithium response 
prediction across different studies. Nevertheless, regardless of the type of lithium 
response explored or whether the investigators found statistically significant results, all 
eight studies recommended further inquiry into the relationship between MMPI results 
and lithium responsiveness. In order to provide the reader with an outline of 
methodological approaches and difficulties, findings, and implications of findings, a 
detailed critique of the eight previously published studies follows. 
Steinbook & Chapman, 1970 
Steinbook and Chapman (1970) coauthored the first published study regarding the 
ability of the MMPI to differentiate between individuals who benefit from lithium 
carbonate treatment and those who do not. Their investigation included 29 participants 
(16 male, 13 female) who were inpatients at a local psychiatric clinic. The affective states 
of participants during the study were not specified, although target symptoms implied 
states of pathological agitation and/or excitation. Examples of target symptoms include: 
“excessive talking,” “hostility,” and “grandiousity” (Stienbook & Chapman, 1970, p. 
525). The study was conducted over a 1-year period, during which patients who were to 
begin lithium treatment were first asked to complete the MMPI. The authors excluded 
those individuals who “responded immediately to the hospital milieu or moderate doses 
of phenothiazines” (p. 254). Additional exclusion criteria included MMPI response sets 
that contained evidence of possible invalidation such as, “random sorts, all true or all 
false response sets, or incompletion” (p. 524). Importantly, MMPI response sets with 
elevated F scales were not excluded, as the authors cited other works indicating, “this is a 
typical finding in highly disturbed patient groups” (p. 524). More recent work also 
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supports the authors’ decision. Writing about the characteristics of the MMPI-2, Nichols 
(2001) reported the F scale is “sensitive to both symptom exaggeration and severe 
psychopathology” (p. 45), and emphasized the importance of interpreting high F scale 
scores in relationship to other validity scores, rather than in isolation. Diagnosis was not 
utilized as a study inclusion criterion, as the authors hypothesized a commonality 
between individuals who benefited from lithium treatment, regardless of diagnosis. 
However, diagnoses were still reported for pre-admission, admission, and discharge, as 
follows: “Manic-depressive, Manic Type,” “Schizoaffective,” “Schizophrenic,” and 
“Other.” 
MMPI’s for each participant were scored for validity and core clinical scales. 
Additionally, the following supplementary scales were calculated: Edwards’ SD (Social 
Desirability) scale, Shaffer’s Ac (Acquiescence) scale, Block’s EC-5 (Ego Control), and 
Welsh’s factor scales A (Anxiety) and R (Repression). SD was evaluated based on 
findings elsewhere that people experiencing mania may be overly concerned with social 
approval. Ac was included based on findings with the Maudsley Personality Inventory 
that people experiencing mania display a yea-saying tendency. The factor dimensions A 
and R were included based on Welsh’s suggestion that bipolar people experiencing mania 
have low scores on these dimensions. Finally, the authors included EC-5 as it was “said 
to measure the same factor as R but to be balanced for acquiescence” (Steinbook & 
Chapman, 1970, p. 528). All scores were K-corrected and reported using T-scores.  
Each participant then received at least one month of lithium carbonate therapy at a 
dose of 900 mg per day or more. Participants’ blood levels of lithium ranged from 0.9 
mEq/L. to 2.0 mEq/L. If “significant improvement had not been evident” (Steinbook & 
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Chapman, 1970, p. 525) after 2 weeks of lithium treatment, phenothiazines were added to 
treatment. The addition of phenothiazines, a class of drugs with known sedative and 
antipsychotic effects (Julien, 2005, pp. 347-350), may have significantly affected 
treatment results. Steinbook and Chapman did not report how many individuals were 
concurrently treated with lithium and phenothiazines. However, they did report that all 
but 2 of the participants were prescribed phenothiazines during the 1-week observation 
period prior to taking the MMPI and beginning lithium treatment. As the authors 
subsequently excluded participants who responded to the initial prescription of 
phenothiazines, it is unlikely that the later re-addition of the drug would account for all 
clinical improvement. However, concurrent lithium and phenothiazine treatment does 
introduce the possible confound of improvement related to drug interaction, rather than 
lithium treatment alone.   
Treatment response in this study was evaluated using daily behavior charting. The 
presence or absence of 17 “lithium target symptoms,” including excessive talking, pushed 
or hurried speech, grandiosity, hostility, etc., were evaluated by nursing staff on a daily 
basis as part of a behavioral charting system. Each participant’s daily scores were then 
totaled and charted as a trend line over the 1-month lithium treatment period. Two 
psychiatrists then independently evaluated the response trends utilizing an 8-point rating 
scale. This rating scale ranged from 1 (“deteriorated and became more psychotic, 
phenothiazines added”), to 8 (“marked improvement”) (Steinbook & Chapman,1970, p. 
526). The two psychiatrist’s ratings for each patient were averaged for final statistical 
analysis (inter-rater correlation was r = .90, p < .01).  
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The authors reported 15 participants (51.72%) showed “moderate to marked 
improvement” (rating scale score of 7 or 8) (Steinbook & Chapman,1970, p. 526). No 
significant correlation was found between lithium response and age, weight, maximum 
lithium blood level, or either preadmission or admission diagnosis. A significant 
correlation was found between lithium response and gender (r = .43, p not reported), with 
more males showing improvement than females. This correlation was likely an artifact of 
the study, as more recent research does not support the existence of significant gender 
differences in lithium response (see Viguera, Tondo, & Baldessarini, 2000, for a meta-
analysis of 17 studies regarding sex differences in lithium response). Additionally, the 
diagnosis of paranoid features prior to, but not at, admission was significantly positively 
correlated with outcome (r = .36, p not reported). The authors also noted, “following 
treatment, there was a noticeable shift toward the diagnosis of manic depressive-manic 
type” and suggested this finding may have indicated “that treating psychiatrists tend to 
equate a positive response to lithium with the diagnosis of manic depressive illness, 
manic type” (Steinbook & Chapman,1970, p. 527). Of the examined MMPI scales, seven 
were reported as having statistically significant correlation with lithium response. In 
order of descending significance, these scales were: Ac (r = .59, p < .01); Ma (r = .56, p < 
.01); K (r = -.56, p < .01), F (r = .47, p < .01); R (r = -.44, p < .05); Mf (r = 0.39, p < .05); 
and D (r = -.38, p < .05). However, multiple regression analysis indicated only the Ac 
scale accounted for a statistically significant amount of the variance. The authors 
concluded that the correlation between Ac scores and their measure of lithium response 
supported the finding that people who respond to lithium exhibit a tendency to answer 
“yes” rather than “no,” regardless of diagnosis. Finally, Steinbook and Chapman 
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concluded the Ac scale held promise for predicting lithium response if their results could 
be confirmed in studies with other patient populations. 
House & Martin, 1975  
Five years after Steinbook and Chapman (1970) posited the ability of the MMPI 
to differentiate lithium responsive patients from non-responsive patients, House and 
Martin (1975) published a study with a different hypothesis; that Scales 2 and 7 
differentiate responders from non-responders. After clinical observation suggested MMPI 
profiles with low magnitude scores on clinical Scales 2 and 7 correlated to lack of 
response to lithium carbonate (and high scores on Scales 2 and 7 correlated to 
responsiveness), the authors constructed a research study to investigate the veracity of 
this apparent correlation.  
House and Martin’s participant pool consisted of 26 inpatients on two research 
wards at the National Institute of Mental Health. Both unipolar and bipolar patients were 
included as participants. However, all participants were judged to be experiencing a 
depressive episode at the time the study commenced and bipolar patients “all showed no 
signs of mania or hypomania” (1975, p. 645). The researchers operationalized current 
depressive episodes as “characterized by psychomotor retardation or agitation, anorexia, 
weight loss, sleep disturbances, depressive thought content (often of psychotic 
proportions), dominated by feelings of hopelessness and worthlessness, preoccupation 
with guilt, and suicidal ideation” (p. 645). These selection criteria differed substantially 
from the procedures of Steinbook and Chapman, whose criteria for improvement did not 
include monitoring depressive symptoms. A psychiatric social worker and a psychiatrist 
diagnosed the participants based on patient interviews, as well as collateral information 
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such as hospital records, family reports, and psychological testing results. Participants 
were administered the MMPI during the first week after their admission and prior to 
beginning any pharmacotherapy. All clinical scales were scored, with the exception of 
Scale 5, for which no reason was given. The omission of this scale without 
methodological justification is of interest, particularly as it ranked among the scales of 
possible statistical significance in Steinbook and Chapman (1970). Scales L, F and K 
were also scored. All scores were K-corrected and reported using T-scores.  
The researchers divided participants into two groups according to MMPI results. 
The “low 2-7 group” (House & Martin, 1975, p. 645) comprised participant profiles for 
which T scores on both Scales 2 and 7 were lower than 70 and for which neither Scale 2 
nor scale 7 fell within the top four rank ordered scales. Conversely, the “high 2-7 group” 
(p. 645) consisted of participants whose profiles yielded T scores of 70 or higher on both 
Scales 2 and 7 and for which both scales were among the top four rank ordered scales. 
Other data collected included various demographic information; time between onset of 
current episode and beginning lithium therapy; and clinical ratings of depression, anxiety, 
and psychosis for 5 days prior to beginning lithium therapy as well as on the day of 
MMPI administration.  
Each participant was provided with a placebo for at least 6 days prior to beginning 
lithium treatment and subsequently was administered lithium for a minimum of 12 days, 
using a double blind delivery process. Current wisdom suggests a steady state of lithium 
in blood plasma is typically reached after 2 weeks of drug administration (Julien, 2005), 
suggesting 12 days may not have been a sufficient period to observe full drug treatment 
effects in this study. Lithium dosage ranged from 900 to 1500 mg per day, with target 
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therapeutic serum levels of 0.7 to 1.3 mEq/L. Each participant’s “mean depression 
rating” (House & Martin, 1975, p. 645) was determined for two time periods, using the 
Bunney-Hamburg Scale, a 24 item scale “which is designed to systematically evaluate 
affective behavior on psychiatric wards” (p. 645). The rating from the first time period, 
which consisted of the 5 days prior to beginning lithium administration, was compared to 
the rating from the second time period, which consisted of the last 5 days of lithium 
administration. Participant response to lithium was then scored according to a rating scale 
derived from change in mean depression rating between the first and second time period. 
On this scale “complete” response consisted of a decrease of 3 or more points, “definite” 
response consisted of a decrease of between 2.0 and 2.9 points, “significant” response 
consisted of a decrease of between 1.4 and 1.9 points, and “‘no improvement’” consisted 
of a decrease of less than 0.6 points, no change, or any increase in points. Improvement 
of 1.4 points or higher was determined to be statistically significant as measured by 
Student’s t test (p.645).  
Five participants met criteria to be included in the “low 2-7 group” and 21 
participants met criteria to be included in the “high 2-7 group.” No low 2-7 group 
participants met criteria for improved depression ratings during lithium administration 
and 4 showed increased depression ratings. In contrast, 17 members of the high 2-7 group 
showed statistically significant improvement. Eight people fell in the complete remission 
category, 6 fell in the definite improvement category, and 3 fell in the significant 
improvement category. The difference in number of participants who responded to 
lithium in the two groups was statistically significant, as determined by the Fisher exact 
probability test (p < .002). All 5 participants in the low 2-7 group were diagnosed with 
                                                                                                                             
   
15
bipolar disorder, while 12 members of the high 2-7 group were diagnosed with bipolar 
and 9 members were diagnosed with unipolar disorder. The difference in number of 
people with each diagnosis in the two groups was not statistically significant according to 
the Fisher test (p < .09). Despite this claimed lack of statistically significant difference, 
House and Martin’s results may still have been impacted by the heterogeneity of their 
sample. Current research suggests that unipolar depression is far less likely to respond to 
lithium as a monotherapy than bipolar depression (Sachs, Lafer, Truman, Noeth, & 
Thibault, 1994). House and Martin noted there were no statistically significant group 
differences on any of the other measured variables, with four exceptions. The low 2-7 
group had a significantly lower depression rating for the period prior to lithium 
administration (although not for the period during which MMPI administration took 
place), had significantly higher rank orders and T-scores for Scales 4 and 9, and had a 
significantly lower rank order and T-score for Scale 3. Specific significance values were 
not reported for these differences.  
In their discussion of results, House and Martin hypothesized there was greater 
utility in using the MMPI to differentiate people whose symptoms were refractory to 
lithium treatment, rather than those who were responsive to the treatment. Regarding this 
hypothesis, they reported, “In our experience, most depressed patients have high 2-7 
profiles. A high 2-7 group may therefore be quite heterogeneous and may include 
subgroups refractory as well as responsive to lithium carbonate” (1975, p. 646). Further, 
the authors called for future research to further examine their findings and to address 
limitations in their investigation such as a small sample size and an absence of 
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participants with less severe depression. In addition, they noted the need to investigate 
the lower depression ratings in the low 2-7 group during the initial rating period.  
Donnelly, Goodwin, Waldman, & Murphy, 1978 
In 1978, Donnelly, Goodwin, Waldman, and Murphy published an investigation 
of the association between pretreatment MMPI responses and behaviorally rated lithium 
response. Similarly to House and Martin (1975) before them, Donnelly et al. sought 
specifically to examine the potential of the MMPI to predict an antidepressant effect. 
However, Donnelly et al.’s methodology differed substantially from either of the 
previous two studies. In fact, the methodologies of these three studies were so different, 
they appear to be measuring different constructs, despite their shared intention to 
investigate lithium response via the MMPI. 
Donnelly, Goodwin, Waldman, and Murphy’s (1978) participant pool included 
both unipolar and bipolar patients and consisted of 53 patients who had been hospitalized 
for a major depressive episode on one of two National Institute of Mental Health (NIMH) 
research inpatient units. Prior to admission, patients were “screened for primary affective 
disorder” (p. 552). Of the 53 participants, 20 individuals (17 females, 3 males) were 
classified as “unipolar,” 17 individuals (12 females, 5 males) were classified as “bipolar 
I”, and 16 individuals (7 females, 9 males) were classified as “bipolar II” (pp. 552-553). 
Subsequent to drug administration trials, participants were randomly assigned to two 
groups (A and B), with the restriction of balancing the groups for gender. Group A (n = 
27) contained 15 people who responded to lithium treatment (“responders”) and 12 who 
did not (“non-responders”). Group B (n = 26) contained 14 responders and 12 non-
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responders. After examining results from Group A, the authors attempted to predict 
responders and non-responders in Group B.  
Participants completed the MMPI during the first 2 weeks after admission, prior 
to beginning pharmacological intervention. For each completed MMPI, scores were K-
corrected. However, raw scores were used rather than T scores for analysis. Donnelly et 
al. reported this choice was made “because several special scales were not included in the 
T score conversion tables” they utilized (1978, p. 553). However, of the eight published 
studies, Donnelly et al. were the only authors to utilize raw scores rather than T scores.   
To establish lithium response, participants were first administered a placebo for 5 
days, and then administered lithium for 28 days. A double blind procedure was utilized 
for lithium and placebo administration. Median lithium dosage was 1500 mg per day and 
blood serum levels ranged from 0.9 -1.30 mEq/L. Members of a nursing research team 
rated participants’ depression levels twice daily, using a multi-item behavior ratings scale 
“developed by Murphy, Miller, Alterman, and Weingartner and derived from previously 
published scales” (Donnelly et al. referenced Murphy, Beigel, Weingartner, et al., 1974, 
and Bunney & Hamburg, 1963 for these scales). Although Donnelly et al. referenced the 
sources of their behavior rating scale, they did not provide information about specific 
items they included on their adaptation. They noted all participating patients received 
depression ratings in the “moderately severe to severe range” on the scale at the time of 
treatment (1978, p. 553). Mean behavioral ratings were later calculated for each patient 
for the 5-day placebo treatment period and for the last 5 days of lithium administration. 
A paired data t test was used to estimate whether each patient experienced a 
statistically significant decrease on the behavior rating scale during lithium 
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administration. Donnelly et al. (1978) operationally defined “responders” as those 
patients whose rating comparison yielded a t value of greater that 2.26, as well as a rating 
decrease average of 2 or more points. By contrast, “non-responders” where operationally 
defined as those patients who did not meet one or both of the above criteria. The authors 
asserted that a 2-point decrease indicated clinically significant change, but not necessarily 
total symptom remission, as corroborated by physician rating. They also noted that they 
only used a paired data t test as a “guide to the mean rating changes in terms of the 
variability in ratings obtained over the 5-day study segments,” given the fact that there 
was “no accepted statistical test for within-individual comparisons as accomplished here” 
(p. 553). A series of three t tests (for women alone, men alone, and women and men 
combined) were also conducted on a total of 65 MMPI scales to determine potential 
differences between the responder and non-responder groups. The 65 scales consisted of 
the 3 validity scales, the 10 clinical scales, and 52 special scales that were selected for 
“relevance to the affective disorders” (p. 553).  
The authors also conducted three series of item analyses (for women alone, men 
alone, and women and men combined) for the 566 MMPI items’ ability to differentiate 
responders from non-responders. Each item was ranked according to its ability to 
correctly identify the two groups (i.e., yield different answers for responders and non-
responders). Subsequently, the best combination of discriminating items was determined, 
based on various item combinations. Then, weights were assigned to various items, based 
on their discriminatory ability. Lastly, the authors determined the best cutting scores. 
After completing item analyses for group A’s responses, the authors attempted to use 
                                                                                                                             
   
19
their empirically derived scales to differentiate between responders and non-responders in 
group B.  
Results of the t test indicated 11 scales demonstrated significant differences 
between the responders and non-responders in the women and men combined group. 
Further, the authors reported only 1 of these 11 scales, Ego Overcontrol (Eo) (taken from 
Dahlstrom & Welsh, 1960), differentiated between the two response groups. (Donnelly et 
al., 1978, p. 554). Eo differentiated between lithium responders, (who received high Eo 
scores) and non-responders (who received low Eo scores) with 73% accuracy. In contrast, 
the authors found each of the other 10 scales to be no better than chance at predicting 
membership in the two groups. Further, they reported similar findings for the women 
only and men only groups. In each gender-specific group, Eo was also the only scale to 
correctly differentiate between responders and non-responders.   
Based on House and Martin’s (1975) findings, Donnelly, et al. (1978) also 
combined groups A and B in order to examine the ability of Scales 2 and 7 to predict 
lithium response. They concluded that their analysis reflected “a trend similar to the 
results of House and Martin” (p. 555) and reported 64% (7 out of 11) of low 2-7 patients 
were non-responders, while 62% (20 out of 32) high 2-7 patients were responders. 
However, they still concluded that “respective high and low 2-7 profiles are not good 
predictors of response to lithium,” citing that Fisher’s exact test, one-tailed, yielded a p 
value of .12 (p. 555). Notably, the authors also pointed out the low 2-7 group’s lack of 
lithium response in House and Martin’s study may have been accounted for by a lack of 
“measurable depressive symptomology” (P. 555), as the group had significantly lower 
behavioral depression ratings prior to lithium administration.   
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Results from the item analyses indicated lithium responders and non-responders 
were most easily discriminated when women’s and men’s responses were examined 
separately. Two separate groups of items were used to create a “lithium response scale 
for females, or LRS-F” and a lithium response scale for males, or “LRS-M” (Donnelly et 
al., 1978, p. 554). {Since this study came out after Dahlstron et al., I suggest you report 
these items in an Appendix.] The LRS-F consisted of 9 items and discriminated between 
responders and non-responders with 89% accuracy for group A (n = 18, 10 responders, 8 
non-responders). The LRS-M also consisted of 9 items and discriminated with 100% 
accuracy for group A (n =9, 5 responders, 4 non-responders). An LRS score of 6 or higher 
indicated lithium responders among both females and males. After obtaining the above 
results, the authors attempted to cross validate their finding by predicting group B’s 
lithium response. Both LRS-F (n =18, 10 responders, 8 non-responders) and LRS-M (n 
=8, 4 responders, 4 non-responders) “discriminated responders from non-responders with 
100% accuracy” (p. 555). Interestingly, the authors also noted that both female and male 
lithium responders “tended to be characterized by a preponderance of ‘false’ answers” (p. 
554). This observation appears contrary to Steinbook and Chapman’s (1970) findings 
regarding a yea-saying tendency via Schaffer’s Ac scale. However, no statistically 
significant differences were noted between groups in tendency to answer “true” or 
“false.” Finally, the authors cautioned that the lithium response scale items should be 
used only within the context of a scale, as the LRS-F and LRS-M scales’ discriminative 
power was greater than any single component item.  The authors also noted when groups 
A and B were combined, diagnosis differentiated lithium response. The “bipolar (I and II) 
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groups showed a greater tendency than the unipolar group to respond to lithium” (p. 555). 
This difference is also substantiated by more recent research (Sachs et al., 1994). 
In their discussion, Donnelly et al. (1978) called for their study to be replicated in 
order to determine the generalizability of their findings. They also critiqued Steinbook 
and Chapman’s conclusion that Schaffer’s Ac scale is a valid predictor of lithium 
response. Donnelly et al. asserted that Ac “is not an especially good predictor” (p. 555). 
They supported this statement by citing results from the index of forecasting efficiency, 
which revealed that, “our margin of error in predicting response-non-response based on 
the acquiescence scores is only 20% less than it would be without using the scores” (p. 
555). Nevertheless, one could argue that a 20% reduction in error measure equates to 
significant clinical utility, particularly when dealing in high stakes predictions. Lithium 
response could be considered such a high stakes prediction, given the time, money, and 
quality of life that may be lost as a result of inaccurate response prediction. 
Burdick & Holmes, 1980 
In 1980, Burdick and Holmes answered Donnelly and colleagues’ call for a 
replication study. Burdick and Holmes’ participant pool consisted of 20 psychiatric 
outpatients (number of male and female participants was not reported). All participants 
“had a history of at least one hospitalization for a major affective disorder” and were 
“diagnosed as having some form of affective disorder of sufficient severity to warrant at 
least a trial period of lithium treatment” (p. 69).  
Burdick and Holmes (1980) did not specify what type of affective episode 
participating patients were being treated for. In contrast, all participants in the Donnelly 
et al. (1978) study had been hospitalized for a major depressive episode. Although 
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Burdick and Holmes reported Donnelly and colleagues included “patients with both 
depressive and manic symptoms” (p. 69), the dominant symptomatology examined in the 
former article was depressive. A second key difference between the samples in these two 
studies was that all participants in the Donnelly et al. study were inpatients, while the 
Burdick and Holmes study included only outpatients. It is probable that the participants in 
the Burdick and Holmes study experienced less severe and/or fewer symptoms than the 
Donnelly participants as outpatients, by definition, are in less distress than inpatients. 
Fewer symptoms and/or lower symptom intensity would make detection of potential 
differences between a lithium responsive and nonresponsive group more difficult. 
Unfortunately, it would be impossible to directly compare the initial symptom 
presentation between the two populations, as the investigations employed different 
measures of baseline symptom presentation and change (a behavior rating scale was used 
in the former study, while clinical judgment was used in the latter). 
Burdick and Holmes’ (1980) collection of MMPI data also diverged from the 
procedures of Donnelly et al. (1978). While all participants in the earlier study completed 
the MMPI prior to lithium administration, Burdick and Holmes’ approach differed. 
Seventeen of Burdick and Holmes’ 20 participants completed the MMPI “within 6 mo. or 
less prior to initiating lithium treatment, while three patients completed the test between 6 
and 12 mo. of beginning lithium” (p. 69). It is not clear from this statement whether the 3 
participants mentioned may have completed the MMPI subsequent to beginning lithium 
treatment. Although the MMPI’s temporal stability is typically considered to be good 
(see Franzen, 2000 for a review), it is possible that a 6 to 12 month gap between MMPI 
and lithium administration could interfere with the detection of any possible patterns 
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among lithium responders and non-responders. Due to the episodic course of bipolar 
disorders, retest reliability among bipolar individuals is presumably likely to be lower 
than for patients in general. Results may not have been reflective of certain state or 
condition-specific features that were present at the time of lithium treatment. 
A final procedural variation involved length of lithium administration. 
Participants in the Burdick and Holmes (1980) study had been taking lithium for between 
6 weeks and 6 years at the time the study was conducted.  Burdick and Holmes noted this 
was a longer treatment interval than the 28 days reported in Donnelly et al. (1978). 
Further, Burdick and Holmes’ results may have been influenced by patients experiencing 
treatment effects of lithium prior to completing the MMPI.  
Participants in Burdick and Holmes (1980) were determined to be either lithium 
responders or non-responders by the clinical judgment of a psychiatrist (p. 69-70). No 
specific information was provided regarding how response was operationally defined, 
other than the statement that non-responders “did not show a significant reduction in 
symptoms, necessitating alternate treatment” (p. 70). Moreover, the authors did not 
specify whether the clinical judgment utilized was rendered by one or by multiple 
psychiatrists. Ten participants (7 female, 3 male) were classified as lithium responders 
and 10 (8 female, 2 male) were classified as non-responders.  
After obtaining the mean Lithium Response Scale (LRS) scores for lithium 
responders and non-responders, Burdick and Holmes conducted a t test to determine 
whether a significant difference existed between the two groups’ means. Subsequently, a 
Fisher’s test was used to determine the accuracy of the scales at classifying the patients. 
Results indicated the 10 lithium responders obtained a mean LRS score of 5.10 (SD = 
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1.70), while the 10 non-responders obtained a mean LRS score of 4.40 (SD = 1.36). 
Further, a t test indicated the difference between these two means was not statistically 
significant (t = .97, p > .05). Additionally, Burdick and Holmes (1980) reported only 1 
female and 1 male lithium responder were correctly classified by the LRS-F and LRS-M, 
while 6 female and 2 male lithium responders yielded scores that would suggest they 
were non-responders. Similarly, 1 male and 4 female non-responders were correctly 
classified, while 1 male and 4 female non-responders obtained LRS scores that would 
suggest they were responders. A Fisher’s test of these data yielded a non-significant 
result (p > .05), suggesting the scales did not accurately classify patients by group. It is 
important to note that the authors did not indicate they conducted the above analyses 
separately for females and males. Perhaps the choice to combine female and male 
patients may have been implemented due to small sample size. Nevertheless, if the results 
from LRS-F and LRS-M were combined, the procedure would represent a significant 
departure from the procedures of Donelley et al. (1978), who stated the importance of 
making this distinction in order to reveal statistical significance. 
Burdick and Holmes (1980) concluded that the LRS scales should be used with 
caution, given that their predictive validity was low with the population in the current 
study. Further, they stated, “We join Donnelly et al. (1978) in their call for further study 
of this potentially useful instrument, but we caution against firm conclusions based on 
scores from the scales until those studies are completed” (p.70).  
Garvey, Johnson, Valentine, & Schuster, 1983 
In 1983, Garvey, Johnson, Valentine, and Schuster published a second study that 
attempted to replicate the results of Donnelly et al. (1978). Like the original study and the 
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replication study by Burdick and Holmes (1980), the study by Garvey et al. was designed 
to specifically examine the association between MMPI characteristics and Lithium 
response as an antidepressant. The participant pool consisted of 48 (34 female, 14 male) 
outpatients at a psychiatric clinic. Mean participant age of females was 40 (SD = 13) and 
mean age of males was 36 (SD = 15). Participant affective diagnoses were reported as 
follows: Unipolar (16 female, 20 male); Bipolar I (3 female, 1 male); and Bipolar II (2 
female, 6 male). Participants were selected from consecutive referrals to the clinic. 
Inclusion criteria included meeting criteria for a major depressive disorder, as 
operationally defined by Spitzer et al.’s (1978) Research Diagnostic Criteria (RDC). 
Exclusion criteria included participants who “had a primary nonaffective RDC diagnosis” 
or participants “with serious medical problems that would preclude treatment with 
lithium” (p. 18).  
The MMPI was administered to all 48 participants prior to medication trials. 
Based on the LRS criteria Donnelly et al. (1978) reported in their study, participants who 
scored 6 or higher on the LRS were assigned to lithium treatment. Those participants who 
scored 5 or lower on the LRS were assigned to a treatment control group. Twenty-one 
participants (13 female, 8 male) were assigned to the lithium treatment group and 
completed the medication trial. In contrast, 27 participants (21 female, 6 male) were 
assigned to the treatment control group, but only 20 completed the medication trial. Data 
were not provided on the gender or affective diagnosis of the participants in the control 
group who completed the medication trial.  
Participants in the treatment control group received one of two tricyclic 
antidepressants, desipramine or amitriptyline, at dosages ranging from 150 mg/ day to 
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250 mg/ day depending on response. Participants in the lithium treatment group initially 
received 900 mg of lithium per day, with increased dosage to achieve steady-state blood 
serum levels between 0.8 and 1.2 mEq/L (lithium levels were measured every 3 days 
during the study). Regarding blood serum levels, the authors noted, “Lower blood levels 
were permitted if clinically significant side effects occurred” (Garvey et al., 1983, p. 18). 
However, Garvey et al. did not specify how low blood serum levels were in such cases. 
Recent recommended guidelines are for serum levels between 0.5 and 0.7 mEq/L, with 
some guidelines allowing up to a maximum level of 1.2 mEq/L (Julien, 2005, p. 312). 
Given this information, it appears likely that adequate blood levels were achieved, even 
for participants who necessitated reduced dosage due to side effects. Mean lithium blood 
serum levels after 2 weeks were 0.67 (+ 0.28) mEq/L, and 0.76 (+ 0.25) mEq/L after 4 
weeks.  
To assess symptom improvement, Garvey and colleagues (1983) administered the 
17-item Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). The measure 
was administered prior to drug treatment and again after 4 weeks of drug treatment. The 
rating scale was administered by, “trained raters who were blind to treatment assignment” 
(p. 18). Treatment response was operationally defined as a 50% or higher reduction in 
HRSD score.  
Garvey et al. (1983) reported that, upon gathering MMPI responses and Lithium 
response data, they utilized a “chi-square for categorical variables and analysis of 
variance for continuous variables,” but that “no variable reached the 0.05 significance 
level” (p. 19). They provided no further detail regarding their procedures for these 
analyses. They also compared the percentage of participants who were accurately 
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predicted to respond to lithium treatment with the percentage that would have been 
expected if no pretreatment selection had been employed (Garvey et al. p. 18).  
Results of analysis indicated 60% (12/20) of participants in the lithium treatment 
group experienced a 50% or greater reduction in HRSD score, while 85% (17/20) of 
treatment control group members experienced the same reduction. Based on these results, 
Garvey et al. (1983) concluded, “The use of the MMPI lithium response scale to predict 
which patients would respond to lithium was no better than would have been expected if 
no pretreatment selection had taken place” (p. 18). Further, they reported there was no 
difference between the unipolar (n = 15) and bipolar (n = 5) subgroups of the lithium 
treatment group in response rate. They asserted both subgroups “experienced a 60% 
response rate” (p.18). However, it is likely this lack of significance between diagnostic 
groups is an artifact of the particular study and its small sample size. Current wisdom 
indicates unipolar depression is less responsive to lithium monotherapy than bipolar 
disorder (Sachs et al., 1994). As the study included three times as many unipolar 
participants as bipolar participants (36 versus 12 individuals), and the treatment control 
group received tricyclic antidepressants (a group of drugs with proven efficacy for 
unipolar depression), the results reported by Garvey et al. may simply reflect the superior 
efficacy of tricyclics over lithium at treating unipolar depression.  
Interestingly, Garvey et al. (1983) also purported to have conducted a “check on 
the validity of the lithium response scale” by comparing the amount of HRSD scale score 
improvement with the LRS scores using Pearson correlations. Using this method, the 
authors found no significant correlations between HRSD score improvement and LRS 
score and no significant correlations between the 4-week HRSD score and LRS score. 
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Range restriction caused by lower starting scores (as would be found in an outpatient 
rather than inpatient population), may account for these insignificant results.  
In their discussion, Garvey et al. (1983) argued, “the ratio of bipolar to unipolar 
patients in a particular study sample should not affect the accuracy of predictions of the 
MMPI lithium response scale” because Donnelly et al. (1978) were able to accurately 
predict the lithium response of both unipolar and bipolar patients (p. 20). However, there 
are notable differences between the samples in these two studies that counter this 
assertion. Participants in Garvey et al.’s study were outpatients, while those in Donnelly 
et al.’s study were inpatients. Additionally, there was a large difference between the 
diagnostic breakdown of participants in the Garvey et al. study (N = 53: 20 unipolar, 17 
bipolar I, and 16 bipolar II) and those in the Donnelly et al. study (N = 48: 36 unipolar, 4 
bipolar I, 8 bipolar II, and 7 drop outs from unknown diagnostic categories). These 
differences lead one to question the validity of the following statement made by Garvey 
and colleagues: “The fact that the study of Donnelly et al. (1978) contained more bipolar 
patients than did our sample (62% vs. 24%) cannot explain our inability to replicate the 
earlier study’s findings” (p. 20). Finally, although Garvey et al.’s findings did not 
replicate the results of Donnelly et al., they nevertheless asserted that the line of research 
“deserves further investigatory attention” (p. 20).  
Campbell & Kimball, 1984 
Shortly after Garvey et al. (1983) attempted the second replication of the study 
reported by Donnelly et al. (1978), Campbell and Kimball (1984) published a third and 
final replication study. Specifically, Campbell and Kimball sought to investigate the 
generalizability of the LRS-F and LRS-M’s utility to a clinical, rather than research, 
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facility. The authors recognized the significant potential of being able to predict lithium 
response with the MMPI. As they stated, “The potential benefits of this clinical procedure 
include reduced patient sequelae and increased compliance, which would lead to early 
success and simplified medical regimens” (p. 706). 
Unlike the original study by Donnelly et al. (1978), and the two prior replication 
studies, the Campbell and Kimball (1984) study involved a retrospective analysis of 
patient records. Specifically, the sample consisted of all patients from a local inpatient 
psychiatric facility who had both received lithium treatment and completed the MMPI 
from 1975 through 1979 (N = 40). A research assistant scored the LRS for each patient 
using Donnelly el al.’s (1978) procedures and tabulated predictions of lithium response 
so that the authors, who determined diagnosis and treatment outcome, were not aware of 
the predictions. Participant’s clinical improvement during lithium administration was 
determined, “based on global judgment after medical record review” (Campbell & 
Kimball, 1984, p. 706). For a patient’s records to be included in the investigation, 
consensus needed to be reached between the treating psychiatrist and the reviewing 
psychiatrist (R. R. Kimball) or between the reviewing psychiatrist and psychologist (D. 
R. Campbell) regarding, “the presence of depression and the success or failure of 
treatment” (p. 706).  
Participants were excluded if they demonstrated “unipolar mania or significant 
characterological problems associated with drug abuse” (p. 706). Patients were also 
excluded if their records held insufficient data to conclude diagnosis or treatment 
response. All participants met research criteria for a major affective disorder, as defined 
by Feighner et al. (1972). The participant pool was further divided into two diagnostic 
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categories: bipolar (N = 21) and “mixed” (N = 19) (p. 706). In another departure from the 
original study, as well as the replication by Burdick and Holmes, Campbell and Kimball 
did not include participants with unipolar depression. Other reported demographic data 
included average length of stay (18.7 days), number of patients who were concurrently 
taking antidepressants (9 individuals), and number of patients who were concurrently 
taking tranquilizers (26 individuals). The authors noted those individuals who were 
prescribed tranquilizers took them “usually briefly for acute symptoms” (706). No 
information was provided about the prescription of antidepressants or tranquilizers during 
the period individuals completed the MMPI. This is important data, as the presence of 
such powerful medications could significantly impact state dependent response patterns. 
Campbell and Kimball reported, “The MMPI was usually completed during the first 3 
days after admission” (p. 706). However, the authors did not report whether patients were 
already receiving lithium treatment at the time they completed the MMPI. Similar to the 
potential for antidepressants or tranquilizers to alter certain responses, the absence or 
presence of lithium in the system of those responsive to lithium may significantly impact 
state dependent responses on the test. In their discussion section, Campbell and Kimball 
did state, “Many of our patients were beginning to experience the effects of initial 
treatment with psychoactive medications while taking the MMPI” (p. 707). Such a 
statement lends credence to the possibility MMPI responses could have been affected by 
medication administration. In their discussion section, Campbell and Kimball described 
the presence of other medications in patients’ systems during evaluation as an inherent 
difference between research settings and clinical settings. Certainly, potentially 
confounding variables are far more difficult to control in a more naturalistic setting.  
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Regarding participant lithium treatment, one of the authors (R. R. Kimball) acted 
as “reviewing psychiatrist” and determined whether the length of lithium administration 
was long enough for each patient’s records to be included in the investigation (Campbell 
& Kimball, 1984, p. 706). No information was provided regarding mean number or range 
of days for lithium administration among participants. This information would have been 
useful, as a more objective standard could have been applied to determine whether 
patients were prescribed lithium long enough to produce a treatment effect. Currently, 2 
weeks of drug administration is considered sufficient to reach a steady state of lithium in 
blood plasma (Julien, 2005, p. 313). Given that the average length of participant inpatient 
stay was18.7 days in Campbell and Kimball’s study, length of lithium administration may 
not have been long enough to produce a treatment effect in a number of participants. 
Further, this average length of stay was shorter than the original study by Donnelly et al., 
as well as both of its prior replications. However, some of Campbell and Kimball’s 
participants were also evaluated 3 or more months after discharge (see information 
regarding the author’s four data sets below). 
Campbell and Kimball described four sources of data that were utilized in their 
clinical improvement rating procedure. The first data set consisted of the records of 
patients who Kimball had treated. Kimball assessed the clinical improvement of these 
individuals and Campbell provided a second opinion. In the second data set, Kimball 
reviewed and provided a second judgment on the records of patients treated by other 
psychiatrists in the facility. In the third data set, Campbell determined follow-up 
treatment response for some patients by interviewing psychiatrists who had treated 
patients for a minimum of 3 months after discharge. The authors noted, “most patients in 
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this sample were included in the first two replications [data sets]” (1984, p. 706). In the 
fourth data set, the authors attempted to more closely replicate the procedure of Donnelly 
et al. (1978) by evaluating the accuracy of response predictions for bipolar depressed 
patients in the first two sets of data. Although all four data sets were described by 
Campbell and Kimball, no operational definitions were given for patient improvement in 
each data set. However, the authors did note in their discussion that their criteria for 
treatment success “can be readily criticized” (p. 707).  
Campbell and Kimball (1984) analyzed their results using the binomial 
distribution set at .50 or “coin toss distribution” (p. 706). Using this procedure, they 
assessed whether the rate of correct prediction of lithium response using the LRS was 
significantly different than what would be expected had patients been randomly assigned 
to predictive groups. The authors justified the use of this procedure by asserting, “the 
basic decision is accurate/inaccurate relative to the original predictors” (p. 707). Based on 
this analysis, the LRS-F and LRS-M scores did not accurately predict lithium response in 
any of the four data sets at a rate that would be considered significant at the .05 level. 
Campbell and Kimball evaluated predictive success by totaling responder and non-
responder predictions together. It may have been more revealing to evaluate the two 
groups separately, particularly as House & Martin (1975) suggested those who respond to 
lithium might constitute a more heterogeneous group than those who do not, using the 
response prediction groups in their study (low 2-7 profiles and high 2-7 profiles). An 
informal review of Campbell and Kimball’s data does indeed suggest that the rate of 
correct prediction appears higher for non-responders than for responders.  
                                                                                                                             
   
33
In their discussion, Campbell and Kimball (1984) explored multiple factors that 
may have contributed to their inability to replicate the results of Donnelly et al. They 
cited “inherent differences between clinical and research settings” such as the presence of 
psychoactive medications in their patients’ systems at the time they completed the MMPI 
(p. 707). Further, they cited possible “underlying socioeconomic differences and other 
selection factors” (p. 707). They reported the mean MMPI depression score in their study 
exceeded that of the mean score in Donnelly et al. (1978) and asserted this information 
led them to conclude their “patients were as depressed as those in the original sample,” 
therefore presumably ruling out the possibility that their sample did not display severe 
enough symptoms to differentiate between responders and non-responders. Nevertheless, 
the difference in mean length of stay between the two samples (28 days versus 18.7 
days), suggests symptom severity may have been greater in the first sample. Campbell 
and Kimball also addressed methodological differences between the two studies 
including: different criteria for evaluating treatment success and inclusion of “patients 
with mixed bipolar disorder of rapidly cycling patients” in their replication study (p. 
707). However, the authors asserted they were still unable to replicate the original 
findings, even after controlling for this latter difference by removing patients with mixed 
bipolar disorder from their sample. Interestingly, they noted, “neither the initial study nor 
this study controlled for spontaneous remission and general placebo effects; the response 
rate in both studies approximates generally accepted placebo response rates” (p. 707). 
Finally Campbell and Kimball noted that the original study was conducted over a short 
time period and was “vulnerable to criticism because the treatment involved is frequently 
used for longer-range prophylactic effects” (p. 707). They purported to have addressed 
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this potential methodological weakness in their own study by examining antidepressant 
responses at discharge and follow-up. Correlation between these two response rates was 
low, but that may be expected, given that the latter group may have included patients not 
included in the first group. Nevertheless, if correlation was low between response at 
discharge and follow up in their own study, it is possible that the significant predictive 
potential noted in Donnelly and colleagues’ study may have been attenuated by time.  
Based on the results of their investigation, and those of Burdick and Holmes 
(1980), Campbell and Kimball (1984) recommended caution in using the LRS-F and 
LRS-M in clinical settings and suggested, “The MMPI procedures developed by Donnelly 
and associates may not provide clinically useful predictors when employed outside of a 
research setting” (p. 707). Nevertheless, Campbell and Kimball asserted, “Further inquiry 
appears warranted” (p. 707).  
An interesting commentary on Campbell and Kimball’s (1984) replication was 
later published by Lane (1985), along with a response from the authors. Lane questioned 
Campbell and Kimball’s assertion that their failure to replicate Donnelly and colleagues’ 
work was due to differences between research and clinical settings. Instead, Lane 
suggested significant conceptual difficulties existed with the original Donnelly article, as 
well as the three replication studies. He argued, “these studies have investigated the 
relationship of a temporally unstable predictor (MMPI data obtained during acute 
episodes) to a temporally unstable criterion (short-term response to lithium)” (p. 1388).  
Indeed, this criticism could be leveled at the body of research on MMPI and 
lithium response as a whole. No consistency exists between the affective states of 
research participants across studies, nor in fact, within several studies. Furthermore, 
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research from the same period as the above studies suggested the MMPI profiles of 
people diagnosed with bipolar disorder were significantly influenced by affective state ( , 
Gottesman, & Tuason, 1982). In their study of 22 individuals (9 male, 13 female) with 
bipolar disorder, Lumry et al. discovered that individuals currently experiencing a manic 
or depressive episode produced MMPI profiles that were significantly elevated in 
patterns commensurate with the participants’ current episodes. In contrast, individuals 
who were experiencing remission and were euthymic did not produce profiles in the 
significantly elevated range.  
Lane suggested an alternative methodology that would address the issues he cited 
in the prior research. He suggested MMPI data be gathered from euthymic participants in 
order to predict long-term stabilization on lithium. Campbell and Kimball responded by 
recognizing the importance of investigating long-term lithium efficacy, but defended the 
relevance of predicting acute response as well. Further, Campbell and Kimball noted, 
although MMPI responses could vary between the onset and remission of affective 
episodes, they could also be stable, depending on the research cited. This academic 
discussion highlights the importance of clear justification for methodological approach in 
this line of research. Over the approximately 20 years subsequent to the above discussion, 
the main factors that have emerged in long-term lithium treatment efficacy have been 
treatment adherence issues rather than drug response (see Julien, 2005, p. 310 for a 
discussion). In contrast, expedient relief of symptoms during acute affective episodes 
remains an important and evolving goal. Therefore, an investigation that is conceptually 
similar to the research of Donnelly and colleagues and subsequent replications appears a 
propos.  
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Steinberg, 1979 
Approximately 1 year after Donnelly et al. (1978) published their study in the 
American Journal of Psychiatry, Steinberg (1979) published another investigation in the 
same publication. Steinberg’s investigative aim varied somewhat from the three 
previously published studies in that its focus was “on the delineation of a symptom 
pattern unique to lithium responders” (p. 568). This statement implies a slightly different 
approach than the other studies, which sought to “predict” lithium response in some way. 
Steinberg’s study was a retrospective analysis of previously existing data. Of the three 
previously published studies, Steinberg recognized only those of Steinbook and Chapman 
(1970), and House and Martin (1975). Steinberg reported these two “studies were 
inconclusive dues to methodological deficiencies” (p. 567). However, he did not 
elaborate on said deficiencies. Steinberg reported two experimental hypotheses to be 
tested in his study: 1) “At least two MMPI scales will significantly differentiate those 
who do and those who do not respond to lithium,” and 2) “No MMPI scale will 
significantly differentiate between patients who do not respond to lithium and patients 
who are receiving other psychotropic drugs” (p. 567). 
Steinberg’s participant pool consisted of the treatment records of 45 (30 male, 15 
female) psychiatric outpatients or “short-term inpatients” between the ages of 19 and 63 
(1979, p. 567). One exclusion criterion was reported: patients who had previously been 
diagnosed with “organic brain dysfunction” were excluded, based on possible confounds 
that may have been introduced to improvement ratings.  
By reviewing treatment records, Steinberg assigned 15 participants each to one of 
three groups: a lithium response group, a lithium non-response group, and a comparison 
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group of participants who were receiving other psychotropic drugs. Regarding formation 
of the lithium response and non-response groups, the author reported group assignment 
was “done retrospectively by inclusion of consecutively admitted relevant cases” (1979, 
p. 567). The author reported that lithium response and non-response group inclusion was 
determined by examining “each patient’s dated medication history” and members of the 
psychotropic comparison group were selected randomly (p. 567). Lithium response was 
operationally defined as stabilization of psychopathology with lithium alone (no 
adjunctive psychotropic medications) over at least 4 weeks. Those patients who required 
adjunctive medications during the 4-week period were included in the non-response 
group, with one exception. If adjunctive medications were initially needed to stabilize 
symptoms prior to lithium reaching therapeutic levels, but subsequently successfully 
removed, individuals were placed in the response group. In these cases, the author 
specified that lithium monotherapy, without the reintroduction of adjunctive medications, 
needed to be established as successful for 4 months to qualify for inclusion in the lithium 
response group. This procedure highlights the frequency of lithium use in conjunction 
with other medications in clinical settings; a phenomenon also encountered by Campbell 
and Kimball (1984) in their retrospective analysis. It also highlights a methodological 
difficulty. By operationally defining lithium response as response to lithium alone, some 
true response reactions may have been missed. Conversely, had such cases been included 
in the lithium response group, false positives may have been introduced, as there would 
be no way to discern whether the response reaction was due to lithium, the adjunctive 
medication, or a combinatory effect. Participants who were included in the psychotropic 
comparison group were prescribed medications including: “phenothiazines, 
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[diben[z]oxepins-or (sic)], butyrophenones, tricyclic antidepressants, and monoamine 
oxidase inhibitors” (p. 568). The author further noted, “Patients in this group had a 
variety of symptoms other than those used as criteria for prescription of lithium” (p. 568). 
Diagnosis was not used as a criterion for group inclusion. Although the majority 
of individuals in the lithium response and non-response groups had been diagnosed with 
“Manic-depressive disorder” individuals with other diagnoses were also included. Other 
diagnoses included: “Schizophrenia”, “Unipolar depression,” “Schizo-affective disorder,” 
“Cyclothymic personality,” “Anxiety reaction,” “Involutional depression,” “Depressive 
reaction,” “Conversion reaction/ depression,” “Psychotic depression,” and “Hysterical 
personality” (Steinberg, 1979).  It is important to note that group distribution did not 
control for number of participants in each diagnostic group. Several diagnostic groups 
were represented in one or some criterion groups, but not in others. 
All participants completed the MMPI prior to any therapeutic drug trials. The 
author asserted this procedure supported the most objective measurement of symptoms 
and symptom patterns. As Steinberg’s investigation was retrospective, the psychotropic 
medications and dosages to be utilized for each patient were determined prior to the study 
by a treating physician. The author reported most patients selected for lithium 
administration had demonstrated “episodically recurring disorders marked by agitation, 
hyperactivity, or excitement” (1979, p. 567). Further, an episodically recurring disorder 
was operationally defined as “at least one documented episode during the 18 months 
prior to their [the patients’] admission” (p. 567). Steinberg did not provide any 
information on the procedures that were utilized for determining symptom improvement. 
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This presents a significant challenge in evaluating the study’s procedures and in its 
replication.  
In his statistical analysis, Steinberg conducted a one-factor between groups 
analysis of variance (ANOVA) for the three validity scales (L, F, and K) and for the 10 
clinical scales in order to ascertain whether any of these scales differed significantly 
between the three patient groups. Subsequently, he conducted post-hoc Newman-Keuls 
tests to determine which patient group accounted for the most variance in the case of 
significant ANOVA results. Analysis of variance revealed significant differences 
between the three patient groups on five scales: Ma (F (2, 42) = 4.4243, p <.01); Si (F (2, 
42) = 6.742, p < .01); D (F (2, 42) = 3.6956, p < .05); Pt (F (2, 42) = 3.0583, p < .05); 
and L (F (2, 42) = 3.3280, p < .05) (1979, p. 568). Newman-Keuls post-hoc tests 
indicated one MMPI scale yielded significantly higher scores in the lithium response 
group than in the non-response group: Ma (W₂=8.77, p < .05). Three scales yielded 
significantly lower scores in the lithium response group than the in the non-response 
group: Si (W₂= 8.15, p < .05); D (W₂= 13.37, p < .05); and Pt (W₂= 14.56, p < .05) (p. 
568). Based on these results, Steinberg concluded that his first experimental hypothesis, 
“At least two MMPI scales will significantly differentiate those who do and those who do 
not respond to lithium,” was confirmed (1979, p. 567). Further, Steinberg described 
differentiating characteristics the members of each group were likely to display, based on 
Harris and Lingoes (1955). For example, he asserted that lower D scale scores “indicates 
that lithium responders experienced less subjective depression, psychomotor retardation, 
physical malfunctioning, mental dullness, and brooding” (p. 568). However, such 
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conclusions cannot be made based on significant scale differences. Item analysis would 
have been useful in order to detect specific patterns at the subscale and item level.  
Newman-Keuls tests also indicated the lithium non-response group “had significantly 
higher L scale scores than the psychotropic group (W₃= 6.27, p < .05)” (p. 568). 
Therefore, Steinberg’s second experimental hypothesis was unsupported (“No MMPI 
scale will significantly differentiate between patients who do not respond to lithium and 
patients who are receiving other psychotropic drugs,” p. 567). The author noted this 
finding may likely have been due to chance and cited the small number of items in the L 
scale as one potential reason for the Newman-Keuls result.  
Steinberg concluded that the study’s results, though “not conclusive” (1979, p. 
568), suggested symptoms unique to lithium responders. He encouraged, “further 
investigations of the psychological test characteristics of a ‘lithium responsive 
syndrome’” (p. 569).  Steinberg also noted two limitations to his study: the predictive 
ability of his findings was yet to be tested, and the small number of female participants 
necessitated caution when applying results to female patients. Further, the author noted, 
“the diagnostic composition of the lithium response group was not as heterogeneous as 
had been anticipated” and recommended future research attempt to replicate results with 
more diagnostically diverse groups (p. 569). An additional limitation could also be added 
to Steinberg’s discussion. The author did not complete a statistical analysis of whether 
lithium response was correlated with diagnostic category. As his patient group 
membership did not control for diagnosis, such an analysis would be vital to ruling out 
the possibility that differences in lithium response among patient groups was simply due 
to differences in lithium response between diagnostic groups. This explanation seems 
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plausible, given the ratio of individuals diagnosed as “Manic-depressive” to the total 
number in the response group (10:15), compared with the ratio of individuals with the 
same diagnosis in the non-response group (7:15).  
Ananth, Engelsmann, & Kiriakos, 1980 
A year after Steinberg (1979) published his study, Ananth, Engelsmann, and 
Kiriakos (1980) published an investigation intended to “explore the usefulness of the 
MMPI in the prediction of lithium response” (p. 151). Ananth and colleagues described 
their experimental design as “an uncontrolled clinical investigation” (p.151). The study 
took place in two psychiatric hospitals located in Montreal, Canada. The original 
participant pool consisted of 59 outpatients (26 males, 33 females). However, only 40 
participants completed the MMPI (gender of these participants was not reported). 
Participants had been diagnosed with “bipolar affective disorders” and had been 
receiving lithium treatment for more than 2 years. The authors noted, “only those patients 
who had a minimum of three episodes in a period of two years were given prophylactic 
lithium therapy” (pp. 151-152). The authors did not specify whether depressive episodes 
were assessed or only manic and/or hypomanic episodes were assessed for this criterion. 
However, information elsewhere in the article on non-responder affective episodes after 
receiving lithium therapy suggests that both manic and depressive episodes were 
assessed. Other exclusion criteria included the elimination of participants who were 
deemed inadequately treated due to two consecutively measured lithium levels lower than 
0.8 mEq/L and of participants who experienced physical illness in addition to bipolar 
disorder. Ananth et al. reported 84% of participants were receiving 900 mg of lithium per 
day or more, with 7% receiving more than 1500 mg/ day and a population wide range 
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between 600 mg and 2400 mg/ day. The experimenters operationally defined lithium 
“responders” as those participants who “had no recurrence of affective episodes and 
functioned at the premorbid level during the last two years of lithium therapy” (p. 151). 
“Non-responders” were operationally defined as those participants who “had psychotic 
episodes during the last two years of lithium therapy in spite of an adequate serum 
lithium level of 0.8 mEq per litre or more and also those who needed additional 
concurrent psychopharmacological agents” (p. 151). Participant functioning was also 
assessed by a psychiatrist who was unaware of MMPI results and who “completed a 
structured schedule” based on information gathered through interviews conducted during 
“regular follow up appointments.” Additionally, “further data were obtained from the 
patients’ medical charts” (p. 152). No further information was reported regarding the type 
of patient information gathered in addition to MMPI responses or regarding the specific 
components of the above mentioned “structured schedule.”  
In their results, Ananth et al. reported 39 participants (66% of the sample) met 
research criteria as lithium responders, while 20 participants (34% of the sample) were 
deemed to be non-responders. Further, the authors noted this response rate indicated an 
approximately “two-third ratio of positive response to lithium therapy” in the studied 
population (1980p. 152). This finding parallels current wisdom that, “lithium is effective 
in treating 60 to 80 percent of acute hypomanic and manic episodes” (Julien, 2005, p. 
310). Participants in the responder group experienced no further affective disorder 
episodes subsequent to the index episodes, while non-responders experienced an average 
of 1.2 Manic and 1.3 Depressive episodes subsequent to receiving lithium therapy. The 
authors asserted that sex distribution among responders appeared to be skewed toward 
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females (73% of female sample were responders, versus 58% of male sample). However, 
a chi-square analysis did not indicate this was a significant difference. Indeed, current 
research does not suggest significant gender differences exist in lithium response 
(Viguera, Tondo, & Baldessarini, 2000). 
Regarding MMPI responses, Ananth et al. reported, “validity scales of both 
groups of patients were within the norm and their averages showed almost no difference” 
(1980p.152). No specific T-score ranges were reported for validity scales. The authors 
reported the following differences between responders and non-responders in diagnostic 
profile scores: “non-responders obtained higher scores on the Psychopathic Deviate, 
Paranoia, and Mania scales and the responders obtained higher scores on the 
Hypochondriasis, Psychasthenia, and Social Introversion scales” (p. 152). Further, the 
authors noted non-responders had a higher average number of scales elevated above a T-
score of 70 (1.8 diagnostic scales), than responders (1.4 diagnostic scales). They also 
reported 67% of non-responders had at least one scale elevated above a T-score of 70, 
while the same was true for only 57% of responders (p. 152). The authors classified the 
aforementioned trends as “conspicuous,” but noted t tests did not indicate statistically 
significant findings. The authors hypothesized that the small sample size may have 
“limited the detection of statistical significance” (p. 153). Secondly, the authors noted 
they were unable to conduct item analysis to discriminate between responders and non-
responders. A third limitation noted by the authors was the lack of opportunity for pre- 
and post-experimental comparison that would have been available, had the MMPI been 
administered at the beginning of lithium therapy rather than after the treatment had been 
established. This author would also expand on Ananth and colleagues’ mention of the 
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limitation presented by the timing of MMPI completion. As participants completed the 
MMPI after lithium treatment had been established, findings of generally elevated T-
scores among non-responders and a higher percentage of non-responders with at least one 
scale score above 70 are not surprising. These trends are likely to be a reflection of the 
first factor (distress), which would be expected in people experiencing an ineffectively 
treated chronic mental illness. This hypothesis is further supported by the authors’ report 
that the responses of 2 non-responders were excluded, due to “high F scale indicating 
unreliable results” (p. 152), while none of the responder profiles were excluded for this 
reason. T-scores for the F scales of the excluded profiles were not reported, but the F 
scale is known to have a high positive loading on the first factor (Nichols, 2001, p. 29). 
Additionally, Ananth and colleagues reported 72% of responders completed the MMPI, 
while only 60% of non-responders did so. Again, severity of symptoms and general 
distress would be expected to make completing a task such as the MMPI more difficult. 
Despite these limitations, promising patterns were noted. Ananth and colleagues 
concluded, “the MMPI may assist in identifying lithium non-responders by generally 
higher scores and, specifically, elevation of the Psychopathic Deviate and Paranoia 
scales” (p. 154). This statement suggests the need for further research.   
Conclusions 
In summary, eight studies have been published in English that examined the 
relationship between MMPI responses and lithium response. All of these studies were 
published between 1970 and 1984 and ranged greatly in methodology and findings. Four 
studies reported statistically significant results (Steinbook & Chapman, 1970; House & 
Martin, 1975; Donnelly, Goodwin, Waldman, & Murphy, 1978; Steinberg, 1979). One 
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study remarked on notable trends in results that fell short of statistical significance. The 
authors of this study hypothesized that small sample size interfered with the ability to 
detect truly significant results (Ananth, Engelsmann, & Kiriakos, 1980). Finally, three 
studies found no significant results (Burdick & Holmes, 1980; Garvey, Johnson, 
Valentine, & Schuster, 1983; and Campbell & Kimball, 1984). The methodology of each 
study was unique and, though containing both strengths and weaknesses, universally left 
room for improvement. Further, only one of the original studies (Donnelly et al., 1978) 
was replicated and none of the three replication studies followed the original study’s 
methodology very closely. Some key methodological differences across the eight studies 
included: the inclusion of participants from various diagnostic categories, different 
sample sizes, different targeted affective states, different measures of lithium response, 
different durations of lithium treatment, different lithium doses and blood plasma ranges, 
and different periods of lithium administration. Table 1 illustrates the specified 
methodological differences between the conducted studies.
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Table 1  
Methodological Differences Between Previous Studies of the MMPI and Lithium Response 
Study  Participant Diagnostic Categories  Na Participant 
affective 
states  
Measure of clinical improvement 
and li response  
Length of li 
treatment 
Li dosage/ blood 
serum level  
MMPI 
relative  
to li  
Steinbook & 
Chapman, 1970 
Manic-depressive, Manic Type; 
Schizoaffective; Schizophrenic; Other 
29  
 
--  Li response score (1-8) derived from 
change  
in 17 behavioral li target symptoms 
1 month (min) 900mg/day (minimum); 
0.9mEq/L – 2.0mEq/L 
Implied 
priorb 
House & Martin, 
1975 
Unipolar; Bipolar  26  
 
depression Li response category (range “no 
improvement” to “complete 
remission”) derived from change in 
mean Bunney-Hamburg Scale 
depression rating 
12 days (min) 900 1500mg/day; 
0.7  – 1.3mEq/L 
Prior 
Donnelly, 
Goodwin, 
Waldman, & 
Murphy, 1978 
Unipolar; Bipolar I; Bipolar II 53  
 
depression 2 point or > decrease in mean score on 
multi-item behavior ratings scale 
based on scales published by Murphy, 
Beigel, Weingartner, et al., 1974, and 
Bunney & Hamburg, 1963 
28 days 900mg/day (median); 
0.9 – 1.30mEq/L 
Prior 
Steinberg, 1979  
 
Manic-depressive; Schizophrenia; Unipolar 
depression; Schizo-affective; Cyclothymic 
personality; Anxiety reaction; Involutional 
depression; Depressive reaction; 
Conversion reaction/ depression; Psychotic 
depression; Hysterical personality 
45 
 
--  Unspecified stabilization of 
psychopathology,  
lack of need for adjunctive 
medicationsc  
4 weeks (min) -- Prior 
Ananth, 
Engelsman, & 
Kiriakos, 1980 
bipolar affective disorders 40  
 
-- Presence of affective episodes during 
last 2 years of li therapy and need for 
adjunctive medications (non-
responders), as determined by medical 
records  
2 years 600mg – 2400mg/day; 
0.8mEq/L (minimum)  
After 
Burdick & 
Holmes, 1980 R  
Unspecified affective disorders 20  
 
-- Remission of symptoms determined 
by clinical judgment 
6 weeks – 6 years -- Mixedd 
Garvy, Johnson, 
Valentine, & 
Schuster, 1983 R 
Bipolar; unipolar 41  
 
depression 50% or greater reduction in Hamilton  
Rating Scale for Depression (HRSD) 
4 weeks 900mg/day (minimum); 
0.8e – 1.2mEq/L 
Prior 
Campbell & 
Kimball, 1984 R 
Affective disorders: bipolar or mixed 40  
 
-- Remission of symptoms determined 
by clinical judgment and record 
review 
-- -- -- 
Note. Dashes indicate information was not reported by authors. Li = lithium; R = Replication 
aSample sizes reflect number of participants who completed all aspects of the study bAlthough not explicitly stated, Steinbook and Chapman imply the MMPI was administered prior to drug therapy on 
p. 526. cThose participants who required adjunctive medications during an initial 4 week period were included in the non-response group, with one exception. If adjunctive medications were initially 
needed to stabilize symptoms prior to lithium reaching therapeutic levels, but subsequently successfully removed, individuals were placed in the response group. dSome participants completed the MMPI 
prior to and some after lithium administration began. ePlasma levels lower than 0.8mEq/L were allowed if significant side effects occurred.
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Table 1 illustrates considerable variation between study samples regarding the 
inclusion of various diagnostic groups. This factor may have a significant impact on 
research findings, particularly in studies in which participants with different diagnoses 
were not evenly distributed among treatment groups. As discussed in the critiques of 
individual studies, the investigations of House and Martin (1975), Steinberg (1979), and 
Garvey et al. (1983) may have been particularly vulnerable to the contamination of 
results by diagnostic categories. Study sample sizes among the eight investigations were 
generally small but also varied, ranging from 20 to 53. Of course, sample sizes in clinical 
investigations are necessarily influenced by participant availability. However, smaller 
samples necessitate certain methodological considerations. For example, although 
Donnelly et al. (1978) had the largest sample size of all the published studies, 53 
participants remains a small sample in absolute terms. Differences also exist in 
participants’ affective states at the time investigations took place. Such differences can 
make comparison between studies difficult. Although the MMPI does measure 
temporally stable personality attributes, it can also be state sensitive, as noted in Lane’s 
(1985) critique of Campbell and Kimball’s (1984) research. Further, this state sensitivity 
is particularly notable among individuals with bipolar disorders (Lumry, Gottesman, & 
Tuason, 1982). Therefore, it could be important to hold constant the initial affective state 
of participants across investigations. This appears particularly pertinent in the case of 
studies that sought to replicate original findings such as Burdick & Holmes (1980) and 
Campbell and Kimball1 (1984). Neither of these two studies specified whether their 
participants were experiencing depressive symptoms, as was reported in the investigation 
they were replicating (Donnelly et al., 1978). Another factor that impedes comparison 
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between studies is the definition of lithium response. Each study utilized a different 
method for operationally defining lithium response. Therefore, the meaning of change 
was different in each study. Further, investigations varied regarding their duration of 
lithium administration. A steady state of lithium is reached in the blood after 
approximately 2 weeks of treatment, therefore; any length of administration shorter that 2 
weeks may not be adequate to assess response. The 12-day lithium prescription period in 
House and Martin (1975) is therefore questionable. Similarly, as Campbell and Kimball 
(1984) did not report the length of their minimum or average lithium administration 
period, it is possible that some participants in their investigation may not have been 
treated for a sufficient length of time. In a related aspect of research design, certain 
studies did not report either lithium dosage or blood serum level ranges among 
participants (Steinberg, 1979; Burdick & Holmes, 1980; Campbell & Kimball, 1984). 
The omission of this information means a reader cannot ascertain whether sufficient 
doses of lithium were administered to attain a treatment effect by current standards. 
Finally, the timing of MMPI administration varied among the different studies. As 
current affective state can impact various aspects of MMPI response, the measure would 
yield most salient information under three circumstances. First, it would ideally be 
administered prior to participants’ access to lithium treatment effects. Second, it would be 
administered at a time participants were not subject to the psychotropic effects of other 
medications. Third, it would be administered with as much temporal proximity to initial 
lithium administration as possible. After reviewing each study according to these three 
criteria, the following authors may have administered the MMPI after the psychotropic 
effects of lithium had been established in some or all participants: Ananth et al. (1980); 
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Burdick & Holmes (1980); and Campbell & Kimball (1984). Secondly, only three of the 
eight studies (House & Martin, 1975; Donnelly et al., 1978; and Steinberg, 1979) 
explicitly stated no other psychotropic drugs were being administered at the time the 
MMPI was completed. Thirdly, only one study (Burdick & Holmes, 1980) reported the 
temporal proximity of MMPI administration to initiation of lithium treatment. Further, in 
this study, the length of time between collection of MMPI data and lithium data for some 
participants (up to 12 months) may have attenuated any relationship between MMPI 
response patterns and lithium responsiveness. However, the controlled and time-limited 
nature of the investigations of Steinbook & Chapman (1970), House & Martin (1975), 
Donnelly et al. (1978), and Garvey et al. (1983) made it likely that MMPI data and 
lithium response information were obtained within a reasonably contiguous period. In 
each of these studies, participants began drug therapy after MMPI administration and 
during a time-limited inpatient stay. For example, Donnelly et al. (1978) specified that 
participants completed the MMPI within 2 weeks of inpatient admission and that lithium 
was administered for 28 days after an initial observation period. Therefore, it is likely that 
the MMPI data were still relevant at the time lithium was administered.  
Methods of statistical analysis and their results also varied across studies. 
Different studies examined various MMPI variables, used diverse methods of statistical 
analysis to assess the relationship between these variables and lithium response, and 
attained divergent results in terms of statistical significance. Table 2 illustrates the 
similarities and differences between studies along these dimensions.
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Table 2 
 
Analytical Differences Between Previous Studies of the MMPI and Lithium Response 
Study Authors MMPI Variables Examined Method(s) of Statistical Analysis Variable(s) with statistically significant finding 
 
Steinbook & Chapman, 1970 
 
Validity Scales 
Clinical Scales 
Block’s EC-5 (Ego Control) 
Edwards’ SD (Social Desirability) 
Shaffer’s Ac (Acquiescence)  
Welsh’s factor Scale A (Anxiety) 
Welsh’s factor Scale R (Repression) 
Pearson’s six signs of psychosis 
Benarick items 
Correlational matrix   MMPI Scales: L**, F**, 2*, 5*, 9**, R*, Ac** 
Multiple linear regression MMPI Scale: Ac (increase in R2 = 0.3524**)  
House & Martin, 1975 
 
Validity Scales 
Clinical Scales (except Scale 5) 
“Low 2-7” Profiles (Scale 2 and Scale 7        
T < 70, neither scale in top four rank ordered) 
“High 2-7” Profiles (Scale 2 and Scale 7       
T > 70, both scales in top four rank ordered) 
 
 
t test Improvement on Bunney-Hamburg Scale > 1.4 points 
Fisher exact probability test Larger number of High 2-7 group members showed 
significant improvement vs. Low 2-7 group** 
Low 2-7 group: higher rank orders and T scores for 
scales 4 and 9****; 
Low 2-7 group: lower rank order and T score for scale 
3**** 
Donnelly, Goodwin, 
Waldman, & Murphy, 1978 
 
Validity Scales 
Clinical Scales 
52 special scalesa 
566 MMPI items 
Low 2-7 and High 2-7 profiles, as per House 
and Martin, 1975 
t test 
 
Eo (Ego Overcontrol): responders received “high Eo” 
scores, non-responders received “low Eo” scoresb 
item analyses LRS-F differentiated between responders and non-
responders with 89% and 100% accuracy in 2 groups; 
LRS-M differentiated between responders and non-
responders with 100% accuracy in each of 2 groups 
Steinberg, 1979  
 
Validity Scales 
Clinical Scales 
 
one-factor between groups ANOVA Scale 9 (F (2, 42)=4.4243**); Scale 0 (F (2, 
42)=6.742**); Scale 2 (F (2, 42)=3.6956*); Scale 7 (F 
(2, 42)=3.0583*); and L scale (F (2, 42)=3.3280*) 
Newman-Keuls tests (post hoc) Higher in response group : Scale 9 (W₂=8.77*) 
Lower in response group: Scale 0 (W₂=8.15*); Scale 2 
(W₂=13.37*); Scale 7 (W₂=14.56*)  
Ananth, Engelsmann, & 
Kiriakos, 1980 
 
Validity Scales 
Clinical Scales 
 
t test None  
Burdick & Holmes, 1980  R 
  
LRS-F and LRS-M, as per Donelly et al., 1978 t test None  
Fisher’s test None  
Garvy, Johnson, Valentine, 
& Schuster, 1983 R 
LRS-F and LRS-M, as per Donelly et al., 1978 Chi-square analysis None  
ANOVA None  
Campbell & Kimball, 1984 
R 
LRS-F and LRS-M, as per Donelly et al., 1978 Binomial distribution set at .50 None 
Note. R = Replication; Validity Scales = MMPI Scales L, F, and K; Clinical Scales = MMPI Scales 1, 2, 3, 4, 5, 6, 7, 8, 9, and 0 
aRaw scores were used when calculating these scales rather than T scores. bCritical value and cut-off score not reported 
*p < .05.  **p < .01. ***p < .002. ****p value not reported. 
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The majority of examined studies included both the MMPI validity scales (L, F, 
and K) and the core clinical scales (Scales 1-0) in their statistical analyses. In addition, 
two studies (Steinbook & Chapman, 1970 and Donnelly et al., 1978) examined a number 
of previously established supplemental scales constructed by other authors. Further, two 
studies examined variables they constructed from MMPI data (House & Martin, 1975 and 
Donnelly et al., 1978). Four studies assessed the newly formulated variables. First, 
Donnelly et al. included an adjunctive analysis that examined the “high 2-7” and “low 2-
7” groups initially utilized in House and Martin (1975). Then, three replication studies 
(Burdick & Holmes, 1980; Garvey, et al., 1983; and Campbell & Kimball, 1984) 
examined the LRS-F and LRS-M scales constructed by Donnelly et al. (1978). Depending 
on which MMPI variables were examined and how lithium response was operationally 
defined (see Table 1), authors employed a number of statistical analyses. The most 
frequently used analyses were t tests (House & Martin, 1975; Donnelly et al., 1978; 
Ananth et al., 1980; and Burdick & Holmes, 1980). Of the examined indexes, the 
following showed a statistically significant ability to differentiate between responders and 
non-responders: Shaffer’s Ac (Acquiescence), “high 2-7” or “low 2-7” groups, Eo (Ego 
Overcontrol), LRS-F and LRS-M, Scale 9, Scale 0, and Scale 2. Clearly, both 
methodology and results varied greatly among the published articles. Nevertheless, 
regardless of differences between significant findings, a unifying theme among all the 
reported studies was the idea that further investigation was needed. 
Despite multiple calls for further research among the published studies and a 
moderate degree of promise exhibited by multiple results, the line of research on the 
association between MMPI results and lithium response appears to have been abandoned 
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by the mid 1980’s. Multiple reasons for this drop-off can be postulated. The most noted 
study among those published appeared to be Donnelly et al. (1978). Given the inability of 
three separate replication studies to attain similar findings to those of Donnelly and 
colleagues, the promise of further investigation may have been rendered doubtful. It is 
true that an arguable case for further replication could be made, as each of the replication 
studies had clear methodological difficulties that rendered comparison between their 
results and those of the original study difficult. However, a publication bias does exist 
toward reporting of significant findings (for a review of the bias toward publication of 
statistically significant results, see Hopewell, Clarke, Oxman, & Dickersin, 2009). 
Therefore, a pattern of three “dead-end” replications could easily discourage further 
replication research. Further, as the efficacy of lithium treatment became better 
understood, trends in research may simply have shifted to examining correlates of 
response to newer drugs. Nevertheless, many reasons mentioned by earlier authors for the 
utility of exploring a relationship between MMPI responses and lithium response remain 
plausible. For example, House and Martin (1975) argued the utility of discerning lithium 
response via the MMPI in addition to utilizing diagnosis as a guide because patients do 
not always respond to a medication in the way their diagnoses would suggest. Today, 
there are still a significant number of Bipolar individuals for whom lithium is not 
effective. One recent source suggested the number of patients refractory to or unable to 
tolerate lithium approximates 40% of those treated (Julien, 2005). Further, House and 
Martin asserted, “Medication trials are costly, time-consuming, and have potential for 
adverse effects” (p. 646). In contrast, they argued the MMPI was “safe, inexpensive, and 
can be scored and evaluated promptly” (p. 646). The MMPI-2 is still one of the most 
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frequently used personality measures among North American inpatient populations 
(Watkins, Campbell, Nieberding, & Hallmark, 1995). In addition, both the MMPI-2 and 
its adolescent counterpart the MMPI-A, can be readily scored and interpreted by hand or 
with the aid of specially designed computer programs.  As a self-report measure that 
generally takes less than 2 hours to complete, the MMPI also represents far less time 
commitment and risk to a patient than a drug trial, particularly given lithium’s narrow 
therapeutic index and the severity of its potential side effects.  Ananth et al. (1980) 
suggested it was important to limit lithium treatment, as much as possible, to only those 
likely to respond to the drug because of lithium’s narrow therapeutic index and the need 
for frequent monitoring of blood levels. Both of these points are also still relevant today. 
Campbell and Kimball (1984) also asserted that the ability to better predict lithium 
response could lead to “reduced patient sequelae and increased compliance, which would 
lead to early success and simplified medical regimens” (p. 706). Today, it is understood 
that the earlier stabilization of bipolar disorder occurs, the less severe the long term 
symptoms and sequelae can be. Further, medication adherence has emerged as a 
significant concern with lithium treatment (Julien, 2005).  
Additionally, a newer dimension of lithium treatment has emerged since the prior 
research was conducted on MMPI responses and lithium response. Lithium is now 
frequently prescribed for juveniles as well as adults. In 2003, Bhangoo et al. reported 
lithium was the second most prescribed medication in their sample of children and 
adolescents with bipolar disorder (divalproex/DVPX being the most frequently 
prescribed). Additionally, multiple reports indicate rates of lithium prescription for 
juveniles have either remained stable or increased in recent years (Bhangoo et al., 2003; 
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Hunkeler et al., 2005; Najjar et al., 2004). This trend is largely attributable to the 
established efficacy of the drug among adults. Despite lithium’s widespread use among 
young people, significant difficulties remain such as potential for toxicity and side effects 
such as weight gain, nausea, polyuria, polydypsia, tremor, acne, and hypothyroidism 
(Kowatch & DeBello, 2003). Further, controlled studies vary widely in their estimate of 
the percentage of juveniles for whom lithium is effective (Kowatch & DeBello). The 
utility of differentiating between potential lithium responders and non-responders in a 
juvenile population prior to drug administration is clear.  
Also, since the adult research on the relationship between MMPI responses and 
lithium response was completed, the utility of the MMPI with an adolescent population 
has increased. With the construction and validation of the MMPI-A, published in 1992 
(Butcher et al.), a new direction for examining the relationship between MMPI responses 
and lithium response has become possible.  
Purpose of the Current Study 
 Given the continued relevance of the reasons for initial research on MMPI 
response patterns and lithium response, the current frequency of lithium prescription in 
juvenile populations, and the availability of an MMPI version specifically tailored to 
adolescent use (the MMPI-A),  it is surprising that research has not been conducted on 
the association between MMPI-A response patterns and lithium response. The current 
study addresses this gap in the research by conducting a pilot study to analyze potential 
relationships between MMPI-A profiles and lithium response in a group of adolescents 
treated in a local inpatient setting. The study investigates the utility of the MMPI-A in 
selecting adolescent candidates for lithium therapy within the examined population. To 
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this end, four specific research hypotheses are put forward based on review of extant 
literature: (a) participants who responded to lithium (“responders”) will obtain 
significantly different raw scores on the reconstructed LRS-F and LRS-M scales than 
participants who did not respond to lithium (“non-responders”), (b) responders and non-
responders will obtain significantly different raw scores on a reconstruction of Shaffer’s 
(1963) Ac scale, (c) responders and non-responders will not obtain significantly different 
T-scores on 3 MMPI-A validity scale scales (L, F, K), and (d) responders and non-
responders will obtain significantly different T-scores on 1 or more of the 10 MMPI-A 
clinical scales (1, 2, 3, 4, 5, 6, 7, 8, 9, and 0). 
 Given the narrow therapeutic index of lithium (recommended serum levels range 
from 0.6-1.2 mEq/L for both adults and children, (Lopez-Larson & Frazier, 2006; Weller, 
Weller, & Fristad, 1986) and its frequent use with adolescents (Bhangoo et al., 2003 
reported 51% of children and adolescents with BPD in their sample were prescribed 
lithium), the current study could have high clinical utility. Findings could lead to 
improvements in the participating facility’s strategy for treating clients with lithium. By 
increasing the accuracy with which lithium responsive adolescent clients can be 
identified, the cost/benefit ratio of treatment could be decreased and the rate of successful 
discharge from the agency increased (N. Reed, personal communication, September 13, 
2006). 
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METHODS 
Participant Characteristics 
 The participant pool for this study consisted of 29 adolescents (14 males and 18 
females). Participants were between the ages of 14 and 18 years and were residents at an 
inpatient mental health facility in the Northwest United States between April 2002 and 
July 2007.  Participant age was calculated based on the date of MMPI-A administration. 
Mean participant age was 16.0 years (SD = 1.2 years). Adolescents aged 13 or younger 
were excluded from the sample. Although the MMPI-A can be used to evaluate some 
“developmentally advanced” 12 and 13 year-olds (Archer & Krishnamurthy, 2002, p. 
31), evaluation of individuals in this age group requires a separate set of norms not 
utilized by the computer scoring software available at the treatment facility. Therefore, 
inclusion of these individuals was considered inappropriate. No direct contact was made 
with participants as the study design entailed a retrospective analysis of a database 
containing data collected during participants’ residence at the facility.  
 Participants were initially selected by searching the treatment facility’s electronic 
patient record database for individuals who had both been prescribed lithium for a 
minimum of 14 days and who had completed the MMPI-A within 90 days prior to 
lithium prescription. However, the majority of patients at the facility completed the 
MMPI-A subsequent to beginning lithium treatment (n = 19) rather than prior to 
beginning lithium treatment (n = 10). Therefore, search criteria were expanded to include 
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individuals who had taken the MMPI-A within 90 days of beginning lithium treatment. In 
order to address the potential influence of taking the MMPI-A prior to or after 
experiencing the effects of lithium, participants were divided into two groups. The 
“pre14” group consisted of participants who completed the MMPI-A prior to or within 
the first 14 days of lithium administration (n = 13) whole the “post14” group consisted of 
participants who completed the measure after at least 14 days of lithium administration (n 
= 16). For the pre14 group, participants who completed the MMPI-A within 14 days of 
beginning lithium administration were included with those who completed the measure 
prior to lithium administration, based on the fact that lithium generally takes up to 14 
days to reach a steady state in blood plasma (Julien, 2005). 
 Although certain prior studies, such as those conducted by House and Martin 
(1975); Donnelly, Goodwin, Waldman, and Murphy (1978); Ananth, Engelsmann, and 
Kiriakos (1980); and Garvey, Johnson, Valentine, and Schuster (1983), limited their 
samples of lithium responders to individuals treated with lithium monotherapy, several 
other studies included individuals who were concurrently taking additional psychotropic 
medications. These latter studies included those conducted by Steinbook and Chapman 
(1970); Steinberg (1979); and Campbell and Kimball (1984). The current study included 
in its sample individuals who were concurrently being treated with lithium and other 
psychotropic medications. This inclusion was a practical decision, as only 3 of the 29 
participants took lithium in the absence of other psychotropic medications. The mean 
number of psychotropic medications taken by participants including lithium was 3.9 
(range, 1-14). Please note, this number does not necessarily indicate number of 
concurrent medications, but rather the total number of medications from different trials 
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during the period lithium was administered. The frequency of polypharmacy found in this 
population is not surprising, given recent literature suggesting combination 
pharmacotherapy is more commonly implemented than monotherapy for treatment of 
juvenile onset bipolar disorder (Lopez-Larson & Frazier, 2006). Individuals were not 
excluded on the basis of high F, L, or K, scale scores. The theoretical justification for this 
decision is as follows: Although extreme elevations in various combinations of these 
scores may lead one to question the validity of other aspects of the MMPI-A profile 
(overreporting, underreporting, etc.), they nevertheless represent a potentially valid 
means of differentiating between responders and non-responders. Participants were not 
excluded based on VRIN (M = 50.03, SD = 6.56) or TRIN (M = 57.59, SD = 4.87) as 
participant T scores for these response inconsistency scales were universally below 65. 
Participants were not excluded based on a diagnosis of intellectual impairment on the 
assumption that, if the MMPI-A had been administered, the individuals had been assessed 
by the administering psychologist as possessing adequate ability to understand the items. 
Finally, diagnosis was not a participant inclusion criterion, as lithium is utilized in the 
treatment of multiple juvenile diagnoses. Further, participants frequently had multiple 
primary Axis I diagnoses and/or experienced change in diagnosis during their inpatient 
treatment. Primary Axis I diagnoses (including at both intake and discharge) are provided 
in Table 3. 
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Table 3 
Number of Participants by Diagnosis 
Diagnosis Intake n Discharge n 
Bipolar I Disorder, most recent episode depressed 0 2 
Bipolar I Disorder most recent episode manic 4 6 
Bipolar I Disorder most recent episode mixed 4 7 
Bipolar Disorder, Not Otherwise Specified 5 6 
Attention Deficit/Hyperactivity Disorder, 
Predominantly Inattentive Type 1 1 
Attention Deficit/Hyperactivity Disorder, Combined 
Type 6 6 
Major Depressive Disorder 6 2 
Dysthymic Disorder 1 0 
Depressive Disorder, Not Otherwise Specified 1 0 
Generalized Anxiety Disorder 0 2 
Social Phobia 0 1 
Posttraumatic Stress Disorder 6 6 
Separation Anxiety Disorder 1 0 
Anxiety Disorder, Not Otherwise Specified 1 1 
Mood Disorder, Not Otherwise Specified 2 1 
Oppositional Defiant Disorder 2 0 
Conduct Disorder 3 0 
Disruptive Behavior Disorder, Not Otherwise 
Specified 0 1 
Parent-Child Relational Problem 4 3 
Schizoaffective Disorder 1 1 
Obsessive Compulsive Disorder 2 1 
Amphetamine Dependence 1 0 
Alcohol Dependence 1 1 
Pervasive Developmental Disorder, Not Otherwise 
Specified 0 1 
Note. N = 29 
 Note that secondary diagnoses were not recorded for this study. At intake, the 
mean number of primary Axis I diagnoses per participant was 1.83 (range, 1-4). By 
contrast, the mean number of primary Axis I diagnoses at discharge was 1.69 (range, 1-
3). The interested reader is referred to Tables A1, A2, and A3 in the Appendix for Welsh 
code information on participants with specific primary diagnoses. 
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Materials and Measures 
 The MMPI-A (Butcher et al., 1992) and the computerized summaries of scores 
and profiles yielded for this instrument (Archer, 2003) were utilized for the current study. 
In addition, a combination of measures were utilized to determine lithium response. The 
Global Assessment of Functioning (GAF) scale (American Psychiatric Association, 
2000) was used to rate participants’ clinical condition at admission to the facility and 
again at discharge. Further, the facility where the research was conducted keeps records 
of critical incidents for inpatients. Categories of critical incidents include: elopement, 
possession of contraband, self-harm, verbal or physical aggression, and property 
destruction. The facility also records instances of patients being placed on suicide 
precautions. Dates of placement on suicide precautions were combined with dates of 
critical incidents and then plotted for each individual over the period of lithium 
administration. The changes in GAF scores, in combination with changes in critical 
incident/suicide precaution scores were used to determine lithium response. 
Research Design and Procedures 
 Data for participants were collected via a retrospective examination of treatment 
records. These records were housed in a secure electronic database at the participating 
treatment facility. The key data collected for each participant included course of 
pharmacotherapy; treatment response as measured by GAF scores, number and type of 
critical incidents during treatment, and placement on suicide precautions; MMPI-A scale 
score computer printouts; and raw MMPI-A item responses. Other collected data 
included: admission and discharge dates, date of MMPI-A administration, admitting 
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presentation and diagnosis (as evaluated by a staff psychiatrist as well as by a Masters 
level intake clinician), and discharge diagnosis. All collected data were de-identified to 
protect client confidentiality. Electronic data were stored in a double password encrypted 
computer file and hard data were stored in a locked filing cabinet. 
Global Assessment of Functioning 
 For each participant, two Global Assessment of Functioning (GAF) scores were 
recorded: one at admission to the facility and one at discharge. The mean number of days 
between recording intake GAF and initial lithium administration was 27.90 (range, 0-
180). The mean number of days between the last day of lithium administration and 
recorded discharge GAF was 33.90 (range, 0-281). Burlingame et al. (2005) reported that 
the GAF was the second most frequently used standardized outcome measure in their 
review of treatment outcome research in severely mentally ill individuals and that the 
GAF score was uniquely suited to measuring treatment outcome among inpatients, given 
the normative procedures for this measure. Difference scores were calculated between the 
two GAF scores for each participant. Those participants whose difference scores 
represented an increase of 2 or more points were preliminarily designated as “lithium 
responders.” No standard currently exists for determining what minimum change in GAF 
score is clinically significant. However, based on reports of previous research using 
change in GAF scores (Greenberg & Rosenheck, 2005), a cut-off score of 2 points was 
determined. Those who obtained difference scores representing an increase in GAF of 
less than 2 points, no change in GAF score, or a decrease in GAF score were 
preliminarily designated as “lithium non-responders.”  
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Critical Incidents and Suicide Precautions 
 Although GAF is a frequently utilized outcome measure in research with inpatient 
populations, it does have weaknesses. Interrater reliability coefficients for GAF scores 
can vary “from modest to excellent” (Burlingame et al., 2005, p. 447) and tend to be less 
reliable when raters have not been specifically trained, as is the case at the host facility 
for this study. Further, the GAF is based on subjective professional judgment and uses 
only one item to measure multiple functional areas (Greenberg & Rosenheck, 2005). 
Therefore, the determination of treatment response was augmented in participants for 
whom critical incidents and placement on suicide precautions occurred (some participants 
had neither critical incidents, nor placement on suicide precautions. For these individuals, 
change in GAF score alone was used to determine treatment response). For those 
participants for whom critical incidents and/or suicide precautions were recorded, 
incidents were graphically plotted to represent number of incidents per month from the 
time lithium administration began, to the time it ended or the patient was discharged. If 
the rate of incidents per month decreased from the first month to the last, an individual 
was designated as a responder. If the number of incidents remained the same or 
increased, an individual was designated as a non-responder.  
 Individuals for whom both GAF scores and critical incident scores were available 
were assigned to responder or non-responder groups according to the following criteria. 
As the more objective criterion, critical incident change score was designated the primary 
variable and assigned greater weight than GAF change score. Therefore, individuals were 
assigned to the responder group if critical incidents decreased regardless of change in 
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GAF score. Individuals were assigned to the non-responder group if critical incidents 
remained the same or increased, regardless of change in GAF score. 
MMPI-A Data  
 After participants were assigned to lithium responder or non-responder groups, 
MMPI-A data were analyzed for each participant, using a database created in SPSS, 
version 17.0 for Windows (SPSS Inc., 2009). Based on scales examined in adult lithium 
response research, the F, L, and K, validity scales and the primary clinical scales (Hs(1), 
D(2), Hy(3), Pd(4), M-F(5), Pa(6), Pt(7), Sc(8), Ma(9), and Si(0)) were examined. 
Additionally, Schaffer’s Acquiescence (Ac) (Shaffer, 1963) scale and the LRS-F and 
LRS-M scales were calculated (Donnelly, Goodwin, Waldman, & Murphy, 1978; 
Steinberg, 1979).  
 The Ac, LRS-F, and LRS-M scales were reconstructed by converting the original 
item numbers for the scales on the MMPI to item numbers on the MMPI-2. Appendix G 
in Greene (2000) was used to convert the item numbers. Subsequently, the MMPI-A was 
searched for corresponding items. Because some items from the MMPI were not included 
in the MMPI-2 and some items from the MMPI-2 differed from MMPI-A items, not all 
items from the original scales could be included in the reconstruction. In the case of Ac, a 
total of 11 items were not available (MMPI item numbers 198, 369, 408, 409, 410, 425, 
447, 465, 478, 503, and 548). Three items were eliminated for the LRS-F and 2 items 
were eliminated for the LRS-M (MMPI item numbers 425, 429, 439, 485, 501, and 554). 
In four instances across the three scales, minor wording differences existed between adult 
MMPI items and MMPI-A items. However, these changes did not affect the general 
meaning of the text. The changes merely updated the vocabulary used (for example, a 
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change from the word “largely” to “mostly”), and made the word tense age-appropriate 
for adolescents (for example, a change from the words “made” and “thought” to “make” 
and “think” when discussing experience with parents). 
Statistical Analyses 
 Independent samples t-tests were conducted to determine main effects in the data. 
These analyses determined whether significant differences existed between lithium 
responder and non-responder mean scores on the following MMPI-A scales: LRS-F, LRS-
M, Ac, L, F, K, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 0. Effect sizes were also calculated for these 
mean differences, using Cohen’s d (Cohen, 1988). Subsequently, independent multiple 
linear regression models were constructed in order to assess for the potential influence of 
MMPI-A completion time on differences between responder and non-responder groups 
on the assessed scales. To control for time of MMPI-A administration, a dummy variable 
was created for the pre14 and post14 administration time groups and then entered into 
linear regression models as a covariate. All statistical analyses were performed with the 
SPSS version 17.0 for Windows (SPSS Inc., 2009). All tests were two-tailed at the 5% 
level of significance. 
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RESULTS 
t-Tests 
Independent samples t-tests were performed to determine whether significant 
differences existed between lithium responder and non-responder mean scores on the 
following MMPI-A scales: LRS-F, LRS-M, Ac, L, F, K, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 0. 
Table 4 displays mean scores and standard deviations for lithium responder and non-
responder groups on the specified scales. (The interested reader may also wish to refer to 
Tables A4 and A5 in the Appendix for scale means and standard deviations of 
participants grouped according to primary diagnosis.) 
Table 4 
 Scale Scores of Responder and Non-responder Groups  
MMPI-A Scale M SD 
 Responder Non-responder Responder Non-responder 
LRS-F 2.09ª 3.00b 1.45 .63 
LRS-M 4.00c 3.80d 1.63 1.79 
Ac 15.67 17.91 4.33 3.75 
L 54.00 56.18 9.27 12.34 
F 57.22 60.45 9.27 12.34 
K 50.33 45.09 12.53 8.94 
1 55.06 59.36 9.18 14.99 
2 59.56 67.18 8.18 12.05 
3 56.78 58.73 12.60 11.71 
4 67.61 63.45 11.08 10.75 
5 50.39 51.27 7.96 10.10 
6 58.94 60.82 10.20 13.37 
7 57.17 59.27 11.70 14.21 
8 58.83 62.73 10.92 15.08 
9 57.11 56.45 11.87 10.87 
0 51.56 57.45 10.53 11.91 
Note. Lithium responder n = 18 and lithium non-responder n = 11 unless otherwise specified. Raw scores 
are reported for LRS-F, LRS-M, and Ac scales, all other scale scores are reported using T scores. 
ªn = 11. bn = 6. cn = 7. dn = 5. 
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Independent samples t-tests indicated no significant differences between the mean 
scale scores of the lithium responder group and non-responder group for each of the 
assessed scales, suggesting no significant difference exists between responder and non-
responder scores on the measured MMPI-A scales. Table 5 displays t values, significance 
values, and effect sizes for differences between lithium responder and non-responder 
group means on the assessed scales. 
Table 5 
Summary of t-Tests Comparing Responder and Non-responder Groups on MMPI-A 
Scales 
MMPI-A Scale t (p) Cohen’s d 
LRS-Fª -1.449 .168 -.77 
LRS-Mb .201 .845 .12 
Ac -1.421 .167 -.55 
L -.542 .592 -.21 
F -1.182 .247 -.45 
K 1.209 .237 .47 
1 -.965 .343 -.38 
2 -2.035 .052 -.79 
3 -.415 .681 -.16 
4 .991 .331 .38 
5 -.262 .795 -.10 
6 -.427 .673 -.17 
7 -.434 .668 -.17 
8 -.806 .427 -.31 
9 .149 .883 .06 
0 -1.394 .175 -.53 
Note. Degrees of freedom (DF) is 27 unless otherwise noted. 
ªDF = 15. bDF = 10.  
 
Effect Sizes 
Although t-tests did not yield significant results, research has made clear the 
relevance and importance of effect sizes to scientific inquiry, independent of statistically 
significant findings (see Schmidt, 1996 for a discussion). Therefore, effect sizes were 
calculated, using Cohen’s d, for the difference between lithium responder and non-
responder group mean scores on the assessed MMPI-A scales. Using Cohen’s (1988) 
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procedure and classification system for small (0.20), medium (0.50), and large (0.80) 
effect sizes, two effect sizes were found to be at the upper end of the medium effect size 
range. When scores for lithium responders (M = 59.56, SD = 8.18) and non-responders 
(M = 67.18, SD = 12.05) were compared on Scale 2, the result was: t(27) = -2.035, p = 
.052. This finding yielded an effect size of -0.79. This result suggests that lithium 
responders had noticeably lower T scores on Scale 2 of the MMPI-A than did lithium 
non-responders. When scores for lithium responders (M = 2.09, SD = 1.45) and non-
responders (M = 3.00, SD = 0.63) were compared on the LRS-F scale, the result was: 
t(15) = -1.449, p = .168. This finding yielded an effect size of -0.77. This result suggests 
that female lithium responders had noticeably lower raw scores on the reconstructed LRS-
F scale of the MMPI-A than did lithium non-responders. 
Multiple Linear Regressions 
As the omnibus tests could not control for time of MMPI-A completion, a 
potentially influential factor, independent multiple linear regression models were 
subsequently constructed in order to account for the potential influence of this variable. 
Dummy variables were created in order to categorize participants into two groups: those 
who completed the MMPI-A prior to or within 14 days of lithium administration (n = 
13), and those who completed the MMPI-A after at least 14 days of lithium 
administration (n = 16). Separate linear regression models were constructed to ascertain 
whether lithium response was a significant predictor of each measured MMPI-A scale 
score before and after time of MMPI-A completion was controlled for. Using this 
procedure, models showed lithium response status was not a significant predictor of 
MMPI-A scale scores for any of the assessed scales before controlling for time of MMPI-
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A administration. When time of MMPI-A administration was controlled for in the 
regression models, lithium response status remained a non-significant predictor of any 
measured MMPI-A scale. Model results for each scale, after time of MMPI-A completion 
was controlled for, are as follows. 
The first two independent regressions included the LRS-F and LRS-M scales, 
originally developed by Donnelly, Goodwin, Waldman, and Murphy (1978). In the first 
regression, lithium response status was not a significant predictor of LRS-F score when 
time of MMPI-A completion was controlled for (β = .054, p = .835). For the second 
regression, lithium response status was not a significant predictor of LRS-M score when 
time of MMPI-A completion was controlled for (β = .392, p = .232). 
The next independent linear regression utilized the Ac scale, which was originally 
developed by Shaffer (1963) and subsequently found to predict lithium response in 
research by Steinbook and Chapman (1970).  In this regression model, lithium response 
status was not a significant predictor of Ac scale score after controlling for time of 
MMPI-A administration (β = -.092, p = .633). 
The next three independent linear regressions utilized MMPI-A validity scales (L, 
F, and K). Lithium response status was not a significant predictor of L scale score after 
controlling for time of MMPI-A administration (β = .116, p = .559). Nor was lithium 
response status a significant predictor of F scale score after controlling for time of 
MMPI-A administration (β = .128, p = .509). Finally, lithium response status was not a 
significant predictor of K scale score after controlling for time of MMPI-A administration 
(β = -.048, p = .805). 
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Lastly, independent linear regressions were also constructed using the 10 clinical 
scales of the MMPI-A (1, 2, 3, 4, 5, 6, 7, 8, 9, and 0). Lithium response status was not a 
significant predictor of Scale 1 (β = .092, p = .638), Scale 2 (β = .012, p = .949), or Scale 
3 (β = -.030, p = .879) scores after controlling for time of MMPI-A administration. Nor 
was lithium response status a significant predictor of Scale 4 (β = -.208, p = .285), Scale 
5 (β = .096, p = .629), or Scale 6 (β = -.109, p = .581) scores after controlling for time of 
MMPI-A administration. Additionally, lithium response status was not a significant 
predictor of Scale 7 (β = -.066, p = .742), Scale 8 (β = -.038, p = .848), Scale 9 (β = -.141, 
p = .478), or Scale 0 (β = .133, p = .489) scores after controlling for time of MMPI-A 
administration.  
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DISCUSSION 
The findings of this study were mixed regarding the utility of the MMPI-A in 
differentiation between lithium responsive and non-responsive adolescents. The omnibus 
test did not reveal a significant main effect. Using independent samples t-tests, no 
significant differences were found between lithium responder and non-responder group 
means on any of the measured MMPI-A scales. Multiple linear regression models were 
also utilized in order to control for the potential influence of group differences between 
those participants who completed the MMPI-A within 14 days of beginning lithium 
administration (pre14 group) and those who completed it after 14 days or more of lithium 
administration (post14 group). Similar to t-test findings, multiple linear regression 
models controlling for time of MMPI-A administration did not yield significant results. 
Nevertheless, effect size results did indicate findings of interest for t-tests.  
Research hypothesis (a) predicted lithium responders and non-responders would 
obtain significantly different scores on reconstructed versions of the LRS-F and LRS-M 
scales, originally developed by Donnelly, Goodwin, Waldman, and Murphy (1978). This 
hypothesis was not supported using both independent samples t-tests and multiple linear 
regression models.  Research hypothesis (b) predicted that lithium responders and non-
responders would obtain significantly different scores on the Ac scale, which was 
originally developed by Shaffer (1963) and subsequently found to predict lithium 
response in research by Steinbook and Chapman (1970). This hypothesis was not 
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supported using an independent samples t-test and a linear regression model. Research 
hypothesis (c) predicted that lithium responders and non-responders would not obtain 
significantly different scores on three MMPI-A validity scales (L, F, and K). This 
hypothesis was confirmed via independent samples t-tests and linear regression models. 
Finally, research hypothesis (d) postulated that lithium responders and non-responders 
would obtain significantly different scores on one or more of the 10 clinical scales of the 
MMPI-A (1, 2, 3, 4, 5, 6, 7, 8, 9, and 0). This hypothesis was not supported using 
independent samples t-tests and linear regression models. 
Despite the lack of significant results using t-tests and multiple linear regression 
models, some findings regarding effect size are worthy of discussion. When Cohen’s d 
was calculated for differences between lithium responder and non-responder group 
means, two effect sizes were noted that fell at the upper end of the medium effect size 
range. The first of these findings was for the LRS-F scale. The difference between lithium 
responders and non-responders on this scale yielded a Cohen’s d of -0.77. Interestingly, 
the direction of this effect indicated that responders are likely to obtain a noticeably lower 
score on the LRS-F scale than non-responders. This finding is in opposition to what 
would be expected, given that Donnelly et al. (1978) designed the scale to differentiate 
lithium responders from non-responders via the former group’s higher scale scores. It is 
important to note that the sample size used to calculate LRS-F (responder n = 11, non-
responder n = 6) was smaller than the sample used for the majority of other measured 
scales (responder n = 18, non-responder n = 11) due to the gender specific nature of the 
scale. Further, the difference between group means on this scale was not significant (t(15) 
= -1.449, p = .168) and there was a more than twofold difference between standard 
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deviation for the two groups’ means on the scale (responder SD = 1.45, non-responder SD 
= .63). Finally, no similar effect was found for the complimentary LRS-M scale. 
Together, these factors suggest the effect is more suggestive of an artifact of the sample 
than of a generalizable difference between lithium responders and non-responders on the 
LRS-F scale.  
The second noteworthy effect was detected in the difference between mean scale 
scores of lithium responders and non-responders on Scale 2. This difference yielded a 
Cohen’s d of -.79. The direction of the effect suggests that lithium responders were likely 
to have noticeably lower scores on Scale 2 than non-responders. This finding is 
interesting, given the tendency of high Scale 2 scores to be associated with higher levels 
of psychotherapeutic engagement among adolescents (Archer & Krishnamurthy, 2002), 
which would intuitively be associated with better treatment response. It is also unusual 
that an apparent trait difference was found on this scale, given Scale 2’s reputation “to 
function more as a state than a trait scale” (Nichols, 2001). Even so, those who do not 
respond to lithium may possess scale specific traits (such as those measured by the 
Harris-Lingoes scales) to a larger degree than those who do respond to lithium. In 
particular, the “lack of hope for the future” (Archer & Krishnamurthy, 2002, p.72) that is 
often associated with elevated Scale 2 scores, may represent a more enduring trait that 
could negatively impact lithium response, or even general treatment response. This is 
supported by research indicating the importance of positive expectation to successful 
psychopharmacological treatment of bipolar individuals (Sajatovic, Jenkins, Cassidy, & 
Muzina, 2009) and to psychotherapeutic treatment in general (see Greenberg, 
Constantino, & Bruce, 2006, for a review).  Alternately, those who respond to lithium 
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may experience a milder form of the global construct of “depression” than those who do 
not respond. The difference between lithium responder and non-responder standard 
deviations from the mean was much smaller for this scale (responder SD = 8.18, non-
responder SD = 12.05) than for LRS-F. Further, although the difference between group 
means on this scale was not significant (t(27) = -2.035, p = .052), the p value was much 
smaller than for any other measured scale. Additionally, one previous study regarding the 
MMPI and lithium response reported a similar finding. Steinberg (1979) found that Scale 
2 scores differed significantly between lithium responder, non-responder, and 
psychotropic comparison groups using ANOVA (F (2, 42) = 3.6956, p < .05). Further, he 
reported Newman-Keuls post-hoc tests indicated lithium responders yielded significantly 
lower Scale 2 scores than non-responders (W₂= 13.37, p < .05). These factors suggest 
that, at the very least, the potential of Scale 2 to differentiate between responders and 
non-responders bears further investigation.  
Limitations 
There are multiple limitations that need to be considered regarding this study of 
the MMPI-A’s ability to differentiate lithium responders and non-responders. First, the 
majority of study participants completed the MMPI-A after beginning lithium treatment 
(n = 19) rather than prior to taking the drug (n = 10). As these individuals may already 
have been experiencing the therapeutic effects of lithium at the time they completed the 
MMPI-A, their response patterns may not have been as reflective of a hypothetical 
responder or non-responder status as they would have been prior to the onset of lithium 
treatment. An attempt was made to control for this possible confound by creating a 
variable to categorize individuals based on length of lithium administration prior to 
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MMPI-A administration. Those who completed the MMPI-A prior to or within the first 
14 days of lithium administration (n = 13) were assigned to the pre14 group and those 
who completed the measure after at least 14 days of lithium administration (n = 16) were 
assigned to the post14 group. This variable was controlled for in the linear regression 
models. However, results indicated membership in a particular administration time group 
did not significantly change the regression model for any of the examined MMPI-A 
scales. 
A second key limitation was the heterogeneity of affective states among 
participants at the time they completed the MMPI-A and the inability to explicitly 
identify those affective states. MMPI profiles of people diagnosed with bipolar disorder 
vary significantly depending on whether they are in an acute phase of their illness and 
what the nature of that phase is (Lumry, Gottesman, & Tuason, 1982). It is expected that 
a similar effect would exist for individuals completing the MMPI-A. Lane (1985) pointed 
out the methodological difficulty of not controlling for this variation when conducting 
lithium response research using the MMPI. In the current study, intake diagnoses were 
available and the proximity of MMPI-A administration to intake date was generally 
close. Therefore, some inferences could be made about the probable affective states of 
some participants. For example, seven individuals had intake diagnoses (Major 
Depressive Disorder, Dysthymic Disorder, or Depressive Disorder NOS) that suggested a 
depressed mood was likely, while four individuals had an intake diagnosis (Bipolar I 
Disorder most, recent episode manic) that suggested a manic or hypomanic mood was 
likely. However, many individuals had intake diagnoses that were not indicative of 
predominant mood at time of MMPI-A administration (for example, Bipolar I Disorder, 
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most recent episode mixed). Therefore, it was not possible to adequately separate 
participants by predominant affective state or to control for this factor when examining 
MMPI-A responses. The reader is referred to the Appendix for presentation of MMPI 
data by participant diagnostic group. Tables A1, A2, and A3 present Welsh codes for 
participants by primary diagnosis. Tables A4 and A5 display means and standard 
deviations for MMPI-A scales by participant diagnostic group. 
A third limitation is that the construct validity of the lithium response variable 
may have been compromised by the measure used to operationalize it. The GAF scores 
used to assess therapeutic response were taken at intake and discharge, rather than 
immediately prior to beginning lithium administration and at the end of data collection or 
upon discontinuation of lithium. The mean number of days between recording intake 
GAF and initial lithium administration was 27.90 (range, 0-180). The mean number of 
days between the last day of lithium administration and recording discharge GAF was 
33.90 (range, 0-281). Only 6 participants had lag times between the discharge GAF and 
lithium discontinuation. Nevertheless, for at least some individuals, GAF scores may not 
have been reflective of functioning prior to lithium administration or of response to 
lithium. An attempt was made to increase the accuracy of treatment improvement 
measures by utilizing change in number of critical incidents as a measure, when possible. 
However, this data was available for 23 of the 29 participants. Additional limitations 
exist regarding the use of GAF scores as a treatment response measure.  Interrater 
reliability coefficients for GAF scores can be relatively low when raters have not been 
trained in standardized GAF rating (Burlingame et al., 2005, p. 447). Further, even when 
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interrater reliability is high, the GAF is based on subjective professional judgment and 
uses only one item to measure multiple functional areas (Greenberg & Rosenheck, 2005).  
 A fourth limitation involves the concurrent or temporally proximal administration 
of psychotropic medications other than lithium. Of the 29 participants, only 3 
(approximately 10%) took lithium in the absence of other psychotropic medications. The 
mean number of psychotropic medications taken by participants, including lithium, was 
3.9 (range, 1-14). This suggests that treatment outcome and/or lithium responsiveness as 
indicated by MMPI-A responses may have been distorted for a large majority of 
participants.  
 A fifth area of limitation pertains to the reconstructed Ac, LRS-F, and LRS-M 
scales. Although continuity was high between these scale items on the MMPI and the 
MMPI-A, differences were noted, as discussed in the Methods section and several items 
from the original scales were not included in the MMPI-A. Further, a scale created for 
use with an adult population may not measure the identical construct in adolescents.  
Finally, although this study was exploratory, its sample size (N = 29, 14 males, 18 
females) was extremely small. Small samples provide little power for statistical analysis 
(see Cohen, 1988) and therefore increase the risk of Type II Error. To address this 
concern, effect sizes were examined for group differences, in addition to significance 
testing.  
Implications and Future Directions 
Despite the lack of significant findings in the current study, future research is 
recommended on the utility of predicting adolescent lithium response with the MMPI-A. 
There continue to be multiple potential benefits to identifying adolescents who respond to 
                                                                                                                             
   
77
lithium and those who do not. Further, the MMPI-A continues to be a highly valid, 
reliable, and easily accessible measure for use with the adolescent population. Moreover, 
results of this study indicated at least one MMPI-A scale shows the potential to 
differentiate between lithium responders and non-responders. An effect size of -0.79 was 
found for the difference between group means on Scale 2, suggesting that lithium 
responders had a noticeably lower score on this scale than non-responders.  It is hoped 
that this exploratory study will lay the foundation for future inquiry. To this end, several 
recommendations can be made for future research. 
 A true experimental design in an acute inpatient setting would be neither ethical 
nor practical, as it would entail inclusion of a control group and thus deny some 
participants access to an established first line of treatment. Similarly, obtaining a sample 
for evaluating lithium monotherapy could be difficult, given the frequent use of 
adjunctive medications in adolescent lithium treatment. The best solution to these 
difficulties would be a prospective longitudinal study. Individuals entering an inpatient 
facility could be screened at intake for potential study participation by participating in 
structured or semi-structured interviews such as the Structured Clinical Interview for 
DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen 
(SCID-I/P W/ PSY SCREEN) (First, Spitzer, Gibbon, & Williams, 2002). Participants 
who had not previously been administered lithium and who were not currently taking 
psychotropic drugs could be assessed and assigned to a group, based on diagnosis and 
current predominant affective state. Concurrently, these participants could complete the 
MMPI-A, and receive structured and standardized assessments of lithium-responsive 
symptoms such as the Bunney-Hamburg global rating scales for mania, depression and 
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psychosis (Bunney & Hamburg, 1963). Additionally, their GAF could be assessed by 
trained assessors with established interrater reliability. Subsequently, those participants 
who were administered lithium monotherapy would be included in a treatment group and 
could be assessed for treatment response over a predetermined length of time, at regular 
intervals, using the same measures conducted at intake. A comparison group could be 
formed including those individuals who received an alternative monotherapy to lithium 
(such as divalproex). Such a group could help to control for the potential effects of such 
extraneous factors as spontaneous remission of symptoms. Using this design, research 
could continue until an adequate sample size was attained (at least 100 participants, 50 
responders and 50 non-responders would be recommended for adequate statistical power) 
and greater construct validity for treatment response could be ensured. Further, division 
of participants by affective state could address potential differences between MMPI-A 
response patterns dependent on this factor.  
 An alternate direction, as originally suggested by Lane (1985), would be to 
conduct a study with euthymic participants in order to determine an association between 
MMPI-A response patterns and a long term measure of treatment stability (such as 
rehospitalization). However, this type of study would necessarily be applicable to an 
outpatient, rather than acute inpatient population and is therefore beyond the scope of this 
discussion. 
 Clearly, further avenues exist to pursue the potential association between lithium 
responsiveness and MMPI-A responses. However, if a useful relationship does exist 
between these two variables, it is not potent enough to be detected by the pre-
experimental methodology utilized in the current study. Therefore, a more strict 
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experimental design is highly recommended if future research is to result in dependable 
findings.
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APPENDIX 
 
Table A1  
 
Welsh Codes by Diagnostic Group at Intake 
Group Participant Number Welsh Code 
Manic   
 8 3”’91+42-5/867:0# K+L-/F: 
 14 4’3+-2/6 58 190:7# K’+-L/F: 
 23 8+65 40-13279/ LF/K: 
 30 269+-13478/5:0# L+F-/K 
Mixed   
 5 59+-413/682:70# LF-K/ 
 6 69 8274’+-01/35: F/L:K# 
 15 60’97+28-41/35: F+-L/K 
 16 1”326’+5-40 789/ L”’+-FK/ 
 18 0-24 978/136:5# F/L:K# 
 25 4+5 37-9286/10: KF/L: 
 27 24”8’0+37-619/5 F’+-L/K: 
 36 2/34615890:7# K+L-/F: 
 38 4’+63 2918/507: K-LF/ 
Depressed   
 3 94”87’26+-531/0: F-/L:K# 
 4 20-74638/159: K+-F/L: 
 10 4-027/89156:3# FL/K 
 22 3”284761’+0-/59: F’K+L- 
 24 23+-5419/6 87:0# L’+K-/F: 
 26 68”70’42+19-35/ F+-/L:K# 
 28 4”9’+562-871/03: FL/K: 
ADHD   
 2 4”238+1-69 70/5: L’+F-/K 
 9 87 4’6+2-91 30/5: F’+-/L:K# 
 12 2’0+-35 46 17/89: FLK/ 
 18 0-24 978/136:5# F/L:K# 
 24 23+-5419/6 87:0# L’+K-/F: 
 36 2/34615890:7# K+L-/F: 
 37 178’9+604-235/ F/L:K# 
Note. See Table A3 for the Welsh Codes of participants who did not fit into one of the specified diagnostic categories.  
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Table A2 
Welsh Codes by Diagnostic Group at Discharge 
Group Participant Number Welsh Code 
Manic   
 5 59+-413/682:70# LF-K/ 
 7 4”67’28+3-5910/ F-/LK: 
 14 4’3+-2/6 58 190:7# K’+-L/F: 
 23 8+65 40-13279/ LF/K: 
 30 269+-13478/5:0# L+F-/K 
 37 178’9+604-235/ F/L:K# 
Mixed    
 2 4”238+1-69 70/5: L’+F-/K 
 3 94”87’26+-531/0: F-/L:K# 
 10 4-027/89156:3# FL/K 
 15 60’97+28-41/35: F+-L/K 
 16 1”326’+5-40 789/ L”’+-FK/ 
 18 0-24 978/136:5# F/L:K# 
 21 0+4798-615/2:3# F/L:K# 
 25 4+5 37-9286/10: KF/L: 
 26 68”70’42+19-35/ F+-/L:K# 
 27 24”8’0+37-619/5 F’+-L/K: 
 28 4”9’+562-871/03: FL/K: 
 36 2/34615890:7# K+L-/F: 
 38 4’+63 2918/507: K-LF/ 
Depressed    
 4 20-74638/159: K+-F/L: 
 6 69 8274’+-01/35: F/L:K# 
 12 2’0+-35 46 17/89: FLK/ 
 22 3”284761’+0-/59: F’K+L- 
 24 23+-5419/6 87:0# L’+K-/F: 
ADHD   
 2 4”238+1-69 70/5: L’+F-/K 
 12 2’0+-35 46 17/89: FLK/ 
 18 0-24 978/136:5# F/L:K# 
 23 8+65 40-13279/ LF/K: 
 24 23+-5419/6 87:0# L’+K-/F: 
 37 178’9+604-235/ F/L:K# 
 38 4’+63 2918/507: K-LF/  
Note. See Table A3 for the Welsh Codes of participants who did not fit into one of the specified diagnostic categories.  
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Table A3 
 
Diagnoses and Welsh Codes for Uncategorized Participants  
Time  Participant 
Number 
Diagnosis Welsh Code 
Intake    
 7  Oppositional Defiant  Disorder  4”67’28+3-5910/ F-/LK: 
 21 Mood Disorder NOS,  
Amphetamine Dependence 
 
0+4798-615/2:3# F/L:K# 
Discharge    
 8 Schizoaffective Disorder 3”’91+42-5/867:0# K+L-/F: 
 9 Posttraumatic Stress Disorder 87 4’6+2-91 30/5: F’+-/L:K# 
Intake and Discharge    
 11 Schizoaffective Disorder  
(Intake)  
 
24’378+-6109/5: F-K/:L# 
  Mood Disorder NOS  
(Discharge) 
 
 
 29 Posttraumatic Stress Disorder 
(Intake and Discharge) 
 
28+0-7436/159: F/KL: 
 34 Mood Disorder NOS 
Posttraumatic Stress Disorder 
(Intake) 
 
1*87”32’4 60+9-/5: LF-/K: 
  Posttraumatic Stress Disorder 
(Discharge) 
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Table A4 
 
MMPI-A Scale Means and Standard Deviations by Diagnostic Group at Admission  
Group Scales  
 
 F L K LRS-Fª LRS-M b 
 
Ac Hs(1) D(2) Hy(3) Pd(4) Mf(5) Pa(6) Pt(7) Sc(8) Ma(9) Si(0) 
Entire Sample 
(N = 29) 
                
     M 54.45 54.83 48.34 2.41 3.92 16.52 56.69 62.45 57.52 66.03 50.72 59.66 57.97 60.31 56.86 53.79 
     SD 7.19 10.38 11.43 1.28 1.62 4.20 11.66 10.33 12.09 10.96 8.66 11.31 12.50 12.54 11.30 11.25 
Bipolar- Manic 
(n = 4) 
                
     M 52.50 61.00 57.75 3.50 3.00 13.75 55.75 58.25 66.25 63.25 50.00 55.25 47.50 53.75 56.75 42.75 
     SD 6.76 5.72 15.02 2.12 1.41 6.18 9.74 8.54 13.72 7.46 8.83 10.78 9.15 10.44 12.04 11.87 
Bipolar- Mixed 
(n = 9) 
                
     M 63.25 56.00 49.50 3.00 4.5 16.00 52.25 61.00 55.00 66.75 54.25 58.00 56.25 57.75 62.25 53.50 
     SD 8.38 9.63 5.23 1.41 2.12 2.16 3.59 20.05 9.20 14.75 14.39 12.52 13.82 9.54 6.95 16.70 
Bipolar- NOS 
(n = 5) 
                
M 53.40 57.00 50.00 2.00 5.33 18.20 55.80 61.80 53.80 60.20 47.40 58.00 50.60 53.20 54.60 51.20 
SD 3.78 15.17 13.87 1.41 0.58  6.10 17.25 10.47 13.88 11.78 9.84 16.84 13.39 12.13 13.85 9.45 
Depressed  
(n = 7) 
                
     M 59.71 53.14 47.86 2.40 4.00 16.43 54.00 62.43 55.00 68.43 52.86 62.14 60.57 62.88 56.86 54.43 
     SD 8.26 7.97 12.29 0.89 0.00 3.41 8.64 5.13 13.00 12.01 8.15 13.53 11.34 15.96 15.87 11.62 
ADHD 
(n = 7) 
                
     M 57.29 57.29 47.71 2.50 3.80 16.86 55.43 61.43 54.86 59.86 48.71 54.00 54.71 56.00 52.43 54.00 
     SD 7.80 12.22 12.71 0.71 2.17 5.27 11.27 6.75 8.86 11.32 8.24 10.42 13.76 12.91 8.92 10.99 
Note. Raw scores are reported for LRS-F, LRS-M, and Ac scales, all other scale scores are reported using T scores. Participants were grouped by primary Axis 1 Mood Disorder where possible. ADHD 
was included as a category because multiple participants did not have a mood disorder diagnosis at intake, but shared a diagnosis of ADHD. Individuals who were the only participants with a given 
diagnosis at intake were not included in calculations and are referred to in Table A3.  
ªn values for LRS-F differ from other measured scales because the scale is gender specific. By diagnostic category, n’s for LRS-F are: Entire Sample, n = 17; Bipolar- Manic, n = 2; Bipolar- Mixed, n = 
2; Bipolar- NOS, n = 2; Depressed, n = 5; and ADHD, n = 0. bn values for LRS-M differ from other measured scales because the scale is gender specific. By diagnostic category, n’s for LRS-F are: 
Entire Sample, n = 12; Bipolar- Manic, n = 2; Bipolar- Mixed, n = 2; Bipolar- NOS, n = 3; Depressed, n = 2; and ADHD, n = 3. 
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Table A5  
 
MMPI-A Scale Means and Standard Deviations by Diagnostic Group at Discharge  
Group Scales  
 
 F 
 
L K LRS-F LRS-M Ac Hs(1) D(2) Hy(3) Pd(4) Mf(5) Pa(6) Pt(7) Sc(8) Ma(9) Si(0) 
Bipolar- Manic 
(n = 6) 
                
     M 57.17 56.50 49.17 2.33 2.67 15.00 57.17 55.83 57.00 65.00 54.83 60.17 54.50 58.50 58.33 48.33 
     SD 6.43 8.31 13.95 2.52 1.15 5.90 11.00 10.87 5.22 11.45 10.38 10.13 15.98 10.67 9.89 12.14 
Bipolar- Mixed 
(n = 7) 
                
     M 59.14 51.71 53.00 2.25 4.33 17.57 53.00 60.57 50.57 68.71 49.14 60.57 59.57 60.14 57.29 59.86 
     SD 8.53 6.10 5.75 1.50 1.53 1.27 5.75 13.79 10.41 9.79 7.93 13.66 10.44 11.96 7.20 12.14 
Bipolar- NOS 
(n = 6) 
                
     M 56.83 60.67 47.83 2.00 5.00 17.33 57.00 63.17 54.50 67.00 52.67 57.50 53.50 56.33 59.33 51.00 
     SD 5.81 14.56 10.03 1.00 1.00 5.13 15.74 7.33 14.12 16.75 11.13 12.85 10.95 11.33 15.64 8.27 
Depressed 
(n = 5) 
                
     M 58.40  54.00  52.00  2.67 5.00 15.80 54.20 66.20 60.80 61.40 50.60 62.20 58.80 60.40 51.20 55.20 
     SD 8.9 10.32 13.36 .58 0.00 4.97 8.96 6.87 10.96 8.91 7.89 13.03 12.22 17.08 15.39 10.26 
ADHD 
(n = 0) c 
                
     M - - - - - - - - - - - - - - - - 
     SD - - - - - - - - - - - - - - - - 
Note. Raw scores are reported for LRS-F, LRS-M, and Ac scales, all other scale scores are reported using T scores. Participants were grouped by primary Axis 1 Mood Disorder where possible. 
Individuals who were the only participants with a given diagnosis at discharge were not included in calculations and are referred to in Table A3.  
ªn values for LRS-F differ from other measured scales because the scale is gender specific. By diagnostic category, n’s for LRS-F are: Bipolar- Manic, n = 3; Bipolar- Mixed, n = 4; Bipolar- NOS, n = 3; 
and Depressed, n = 3.  
bn values for LRS-M differ from other measured scales because the scale is gender specific. By diagnostic category, n’s for LRS-F are: Bipolar- Manic, n = 3; Bipolar- Mixed, n = 3; Bipolar- NOS, n = 3; 
and Depressed, n = 2. 
cAlthough multiple participants had an ADHD diagnosis at discharge, no individuals had this diagnosis in the absence of primary mood disorder diagnoses. 
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